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ABSTRACT OF DISSERTATION

APPLICATIONS OF ANTIOXIDANT AND ANTI-INFLAMMATORY POLYMERS
TO INHIBIT INJURY AND DISEASE
There is an undeniable link between oxidative stress, inflammation, and disease.
Currently, approaches using antioxidant therapies have been largely unsuccessful due to
poor delivery and bioavailability. Responding to these limitations, we have developed
classes of polymer and delivery systems that can overcome the challenges of antioxidant
and anti-inflammatory therapy.
In our initial studies, nanoparticles of poly(trolox), a polymeric form of trolox, were
surface-modified with antibodies. This modification allows for specific targeting to
endothelial cells, affording controllable and localized protection against oxidative stress.
We have shown these targeted nanoparticles bind, internalize, and provide protection
against oxidative stress generation and cytotoxicity from iron oxide nanoparticles.
In a similar fashion, we have tested the ability of poly(trolox) to prevent rheumatoid
arthritis in vivo. Poly(trolox) nanoparticles were encapsulated in a PEGylated polymer to
enhance circulation and biocompatibility. These particles were shown to accumulate in
inflamed joint tissue, recover natural antioxidant function, suppress protein oxidation,
and inhibit inflammatory markers.
Lastly, we developed a class of polyphenolic compounds utilizing a non-free radical
based reaction chemistry of poly(β-amino esters). The polyphenol apigenin was
investigated for its anti-inflammatory properties to inhibit inflammation-mediated tumor
cell metastasis. PEGylated nanoparticles that incorporated apigenin poly(β-amino ester)
were developed and found to retain their anti-inflammatory efficacy while providing a
long term release profile. These inhibited the ability of tumor cells to adhere to inflamed
vascular cells. We also have shown that these polymers can suppress markers of
inflammation responsible in enhancing tumor cell adhesion.

KEYWORDS: Oxidative Stress, Inflammation, Antioxidant Polymers, Nanoparticles,
Targeting

David Cochran
9/12/2013

APPLICATIONS OF ANTIOXIDANT AND ANTI-INFLAMMATORY POLYMERS
TO INHIBIT INJURY AND DISEASE

By
David B. Cochran

Dr. Thomas D. Dziubla
Director of Dissertation
Dr. Thomas D. Dziubla
Co-Director of Graduate Studies
September 12th, 2013
Date

DEDICATION
I dedicate this body of work and degree to:
Karen and Tom Swenson
Andrea Leydet
Thank you for the continued support and love throughout the ordeals of research.

ACKNOWLEDGEMENTS

While this dissertation is a body of individual work, it could not be possible
without the help and direction of multiple people. First I would like to thank Dr. Thomas
Dziubla for his continued support and guidance during the past four years. He has not
only been a mentor and an advisor, but also a friend.
I’d also like to acknowledge the collaborative efforts and
advisement from Dr. Kimberly Anderson and Dr. Richard Eitel. As my IGERT mentors,
they have helped me succeed and grow in my scientific endeavors. Other collaborators,
such as Dr. Hilt, Dr. Crofford, Dr. Yokel, and Dr. Bradley have also played extremely
pivotal roles in my doctoral studies.
I am grateful for my fellow labmates, Paritosh Wattamwar, John
Medley, Sundar Prasanth, Andrew Vasilakes, and Prachi Gupta. In addition I’d like to
thank my friends, Robert Wydra, Nathaniel Stocke, Jennifer Fischer, and Daniel Schlipf.
Without everyone’s support, I would not be where I am today.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................................ iii
LIST OF TABLES ........................................................................................................................ viii
LIST OF FIGURES ........................................................................................................................ ix
Chapter 1. Introduction................................................................................................................. 1
Chapter 2. Background ................................................................................................................. 5
2.1

Introduction .......................................................................................................................... 5

2.2

Oxidative stress .................................................................................................................... 5

2.3

Mechanisms of oxidative stress ........................................................................................... 6

2.4

Oxidative stress in relation to biocompatibility ................................................................... 9

2.5

Mechanism of immune response.......................................................................................... 9

2.6

Examples in practice .......................................................................................................... 14

2.7

Antioxidant polymers in drug delivery .............................................................................. 18

2.8

Uses as active pharmaceutical ingredients ......................................................................... 18

2.9

Uses as pharmaceutical excipients ..................................................................................... 20

2.10

Antioxidant polymers in anti-cancer therapies .................................................................. 23

2.11

Antioxidant polymers in wound healing and tissue engineering ....................................... 25

2.12

Antioxidant polymers incorporated into biomaterials........................................................ 27

2.13

Direct prevention of implant failure................................................................................... 27

2.14

Mitigation of toxic side effects .......................................................................................... 29

2.15

Stimulation of direct wound healing .................................................................................. 32

2.16

Conclusions and perspectives ............................................................................................ 32

Chapter 3. Research Goals ............................................................................................................. 35
3.1

Introduction ........................................................................................................................ 35

3.2

Objectives and Significance ............................................................................................... 35

3.2.1

Specific Aim 1: Utilization of targeted antioxidant nanoparticles to inhibit iron oxide
nanoparticle injury ......................................................................................................... 36

3.2.1.1

Hypothesis #1................................................................................................................. 36

3.2.1.2

Significance and Outcome ............................................................................................. 36

3.2.2

Specific aim 2: Utilize Poly(trolox) nanoparticles to treat the damage caused by
rheumatoid arthritis in vivo ............................................................................................ 37

3.2.2.1

Hypothesis #2................................................................................................................. 37

3.2.2.2

Significance and Outcome ............................................................................................. 37

iv

3.2.3

Specific Aim 3: Develop a novel anti-inflammatory polymer delivery system to inhibit
the incidence of cancer metastasis ................................................................................. 38

3.2.3.1

Hypothesis #3................................................................................................................. 38

3.2.3.2

Significance and Outcome ............................................................................................. 38

Chapter 4. Suppression of Iron Oxide Injury ........................................................................... 39
4.1

Introduction ........................................................................................................................ 39

4.2

Materials and Methods ....................................................................................................... 41

4.2.1

Reagents ......................................................................................................................... 41

4.2.2

Citric acid coated iron oxide nanoparticle formulation.................................................. 42

4.2.3

Poly(trolox) nanoparticle formulation and characterization .......................................... 42

4.2.4

Antibody loading and characterization .......................................................................... 43

4.2.5

Antibody and particle binding to HUVEC model .......................................................... 43

4.2.6

In Vitro iron oxide nanoparticle toxicity assessment ..................................................... 43

4.2.7

In Vitro cellular protection against background oxidative stress ................................... 44

4.2.8

In Vitro cellular protection against iron oxide induced oxidative stress ........................ 44

4.2.9

Determination of particle internalization ....................................................................... 45

4.3

Results ................................................................................................................................ 46

4.3.1

Poly(trolox) nanoparticle synthesis and characterization .............................................. 46

4.3.2

Antibody coating and stability determination ................................................................ 46

4.3.3

Iron oxide nanoparticles exhibit toxicity and ROS generation in Human Umbilical Vein
Endothelial Cells (HUVEC) .......................................................................................... 50

4.3.4

AntiPECAM-1 and AntiPECAM-1/PTx nanoparticles bind specifically to HUVECs.. 50

4.3.5

Antioxidant function of AntiPECAM-1/PTx nanoparticles in HUVECs ...................... 51

4.3.6

Suppression of iron oxide nanoparticle induced ROS injury through the use of
AntiPECAM-1/PTx........................................................................................................ 53

4.3.7

Determination of iron oxide nanoparticle injury suppression mechanism..................... 54

4.3.8

AntiPECAM-1 coated fluorescent particles exhibit significant internalization following
incubation....................................................................................................................... 59

4.4

Discussion .......................................................................................................................... 63

4.5

Conclusions ........................................................................................................................ 69

Chapter 5. Inhibition of inflammation-mediated rheumatoid arthritis .................................. 70
5.1

Introduction ........................................................................................................................ 70

5.2

Materials and Methods ....................................................................................................... 71

5.2.1

Polymer synthesis .......................................................................................................... 71

5.2.2

Nanoparticle formulation and characterization .............................................................. 71

5.2.3

Induction of arthritis in vivo and treatment regimen ...................................................... 72
v

5.2.4

Assessment of nanoparticle accumulation in vivo ......................................................... 73

5.2.5

Determination of endogenous antioxidant activity in liver. ........................................... 73

5.2.6

Protein oxidation of paw tissue ...................................................................................... 74

5.3

Results ................................................................................................................................ 75

5.3.1

Nanoparticle formulation and characterization .............................................................. 75

5.3.2

Assessment of mPEG-PLA/PTx nanoparticles to suppress rheumatoid arthritis .......... 75

5.3.3

mPEG-PLA/PTx nanoparticles accumulate in organs and joints .................................. 79

5.3.4

Endogenous antioxidant activity is recovered through the use of mPEG-PLA/PTx
nanoparticles .................................................................................................................. 79

5.3.5

mPEG-PLA/PTx significantly inhibits protein carbonyl content. ................................. 81

5.3.6

Antioxidant nanoparticles reduce levels of inflammatory cytokines associated with
oxidative stress ............................................................................................................... 81

5.4

Discussion .......................................................................................................................... 81

5.5

Conclusions ........................................................................................................................ 85

Chapter 6. Interrupting the Metastatic Cascade: Apigenin-based Polymer Nanoparticles
Inhibit Cancer Cell Adhesion ..................................................................................................... 86
6.1

Introduction ........................................................................................................................ 86

6.2

Materials and Methods ....................................................................................................... 90

6.2.1

Polymer synthesis .......................................................................................................... 90

6.2.2

Degradation of apigenin PβAE films ............................................................................. 91

6.2.3

Nanoparticle formulation and characterization .............................................................. 91

6.2.4

In vitro drug release ....................................................................................................... 93

6.2.5

Cell culture ..................................................................................................................... 93

6.2.6

Cell viability................................................................................................................... 94

6.2.7

Determination of tumor cell adhesion in cell culture ..................................................... 94

6.2.8

Time-dependent apigenin PβAE release in cell culture ................................................. 95

6.2.9

Quantification of inflammation suppression .................................................................. 95

6.3

Results ................................................................................................................................ 96

6.3.1

Characterization of apigenin multiacrylate .................................................................... 96

6.3.2

Apigenin PβAE polymerization and characterization .................................................... 96

6.3.3

Characterization of nanoparticle formulations and release profiles ............................. 100

6.3.4

Evaluation of apigenin and apigenin PβAE capability ................................................ 100

6.3.5

Apigenin and apigenin PβAE nanoparticles tumor adhesion suppression capacity..... 104

6.3.6

Extended release of apigenin PβAE nanoparticles provides potential long term tumor
cell adhesion suppression ............................................................................................. 107

6.3.7

Evaluation of inflammatory intracellular adhesion molecule (ICAM-1) expression ... 107
vi

6.4

Discussion ........................................................................................................................ 110

6.5

Conclusions ...................................................................................................................... 114

Chapter 7. Conclusions.............................................................................................................. 117
APPENDIX ................................................................................................................................. 119
REFERENCES........................................................................................................................... 145
VITA ........................................................................................................................................... 162

vii

LIST OF TABLES
Table 2-1.
Table 2-2.
Table 2-3.
Table 5-1.
Table 6-1.

Reactive Molecules and Their Sources ............................................................8
Summary of the Biomaterial Induced Inflammatory Response .....................11
Antioxidant Polymers and Their Application.................................................34
Properties of mPEG-PLA nanoparticles .........................................................77
Nanoparticle characterization summary .......................................................102

viii

LIST OF FIGURES
Figure 2-1.
Figure 2-2.
Figure 2-3.
Figure 2-4.
Figure 4-1.
Figure 4-2.
Figure 4-3.
Figure 4-4.
Figure 4-5.
Figure 4-6.
Figure 4-7.
Figure 5-1.
Figure 5-2.
Figure 5-3.
Figure 5-4.
Figure 6-1.
Figure 6-2.
Figure 6-3.
Figure 6-4.
Figure 6-5.
Figure 6-6.
Figure 6-7.
Figure 6-8.
Figure 6-9.
Figure 6-10.
Figure 6-11.
Figure 6-12.
Figure 6-13.

A hypothetical model illustrating the mechanism of ROS and implant
inflammation ......................................................................................... 17
Effect of antioxidants on light-induced oxidation of rhuMAb HER2
formulation............................................................................................ 22
Cytotoxicity of PCurc 8 to SKOV-3, OVCAR-3, and MCF-7 cancer cell
lines ....................................................................................................... 26
Effect of SODm grafting on polymer implants ....................................... 31
Characterization of poly(trolox) nanoparticles ....................................... 48
Iron oxide toxicity and ROS in HUVECs ............................................... 52
Antibody and particle binding to cellular model with suppression of
background ROS ................................................................................... 55
Suppression of iron oxide injury ............................................................. 57
Determination of protection mechanism ................................................. 61
Particle adherence and internalization .................................................... 66
Proposed protection mechanism of antiPECAM-1/PTx nanoparticles ... 68
Analysis of arthritis score and animal weight over time ......................... 78
Fluorescent images of nanoparticle accumulation in vivo ...................... 80
Ability of mPEG-PLA/PTx to recover antioxidant capacity .................. 82
Suppression of protein carbonyl content of paw tissue ........................... 82
Reaction schematic of apigenin to apigenin multiacrylate ..................... 97
Reaction schematic for creation of apigenin PβAE ................................ 97
1H-NMR analysis of apigenin and apigenin multiacrylate ..................... 98
FT-IR analysis of apigenin and apigenin multiacrylate .......................... 99
FT-IR analysis of apigenin multiacrylate and the polymer apigenin PβAE
............................................................................................................... 99
Nanoparticle in vitro release profile ...................................................... 102
Apigenin and apigenin PβAE degradation product toxicity ................. 103
Apigenin and apigenin PβAE tumor cell suppression activity ............. 105
Apigenin and apigenin PβAE nanoparticle toxicity profile .................. 106
Apigenin and apigenin PβAE nanoparticle tumor cell suppression activity
............................................................................................................. 108
Long-term release of apigenin PβAE and tumor suppression activity.. 109
Inflammatory CAM expression in HUVECs ........................................ 111
Tumor cell adhesion verses ICAM-1 expression .................................. 116

ix

Chapter 1. Introduction

Oxidative stress is a key pathological process in a variety of disease states (e.g.,
ischemia-reperfusion injury [1, 2], hypoxia, and acute lung [3] and renal injury [4]).
Oxidative stress is characterized by the formation of a wide range of reactive oxygen
species (ROS), which cause an altered cellular redox state leading to severe DNA, protein,
and lipid damage; ultimately resulting in dysfunction and death [5, 6].
In addition to the direct lipid and DNA damage caused, oxidative stress can cause cells
to produce cytokines and chemokines that play a role in propagation of the inflammatory
response [7] such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor
alpha (TNF-α) [8, 9]. This inflammatory response can in turn induce pathway activations
such as the NF-кB [10], ERK [11], and JNK pathway [12], among others. This activation
initiates a cascade of gene activation to regulate antioxidant and immune defenses [13].
Endothelial cells, in response to this pathway activation, begin to secrete and express
molecules known as Cellular Adhesion Molecules (CAM) on their surfaces to facilitate
leukocyte adhesion, vasodilatation, and transmigration [14]. Likewise, immune system
cells will respond in kind to secrete nitric oxide as a host defense mechanism against
pathogens [15]. Under normal conditions, recruited leukocytes, macrophages, and
neutrophils will contain and mitigate further damage. However, in some cases the immune
system cannot regulate its defenses due to factors such as persistent infections [16],
complications with implanted “biomaterials” [17], or depletion of natural antioxidant
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reserves [18]. In these scenarios the immune response can begin to damage viable cells
through uncontrolled cytokine production [19].
It is possible to inhibit and reverse these events through supplementation of free radical
scavengers, which can intercept ROS; thereby attenuate cellular damage [20-22]. Recently,
certain antioxidants have also been shown to suppress some specific inflammationmediated pathways. For example quercetin, a naturally-derived flavanol, can down regulate
Intercellular Adhesion Molecule-1 via inhibiting the ERK-1 pathway [23, 24].
Antioxidants, simply defined, are molecules that can inhibit the oxidation potential of
other molecules, such as free radicals. They are broken down into two general categories,
small molecule and enzymatic antioxidants. Heavy interest lies in small molecule
antioxidants, which unlike antioxidant enzymes can scavenge a large array of free radicals
rather than one specific substrate [25-27]. Despite this advantage, there are still many
obstacles to overcome for effective treatment using small molecule antioxidants, most
notability in the delivery methods [28, 29].
In addition to the antioxidant benefits, researchers have discovered how certain classes
of antioxidants can modulate cellular responses and pathway activation or deactivation [3032]. It has been observed that flavonoids such as quercetin and epicatechin not only inhibit
oxidative stress [33, 34], but can suppress the inflammatory pathways NF-κB and AP-1
through inhibition of specific kinase pathways by prevention of transcription factor
phosphorylation [31, 35]. Interestingly, quercetin is the only reported flavanol with the
ability to suppress both NF-κB activation and the JNK pathway [36, 37]. Flavones on the
other hand, have been reported to suppress JNK, ERK, and NF-κB pathways, leading to
down regulation of ICAM-1, VCAM-1, and E-selectin [36], making them great candidates
2

for applications such as cancer metastasis prevention [38, 39]. Apigenin is of special
importance as it is shown to be one of the most potent flavones tested for suppression of
these multiple inflammatory pathways [36]. As such, apigenin has been selected as the
molecule of interest to formulate into an antioxidant polymer for delivery.
While flavonoids have poor water solubility, short biological half-life, and non-specific
cellular uptake, these can be overcome utilizing the polymerization strategies described
above. Lastly, while trolox, vitamin E, and possibly poly(trolox) show similar recovery
effects as the flavanol quercetin in that they can suppress ICAM-1 expression, they do not
affect VCAM-1 or E-selectin levels [40], further strengthening the use of apigenin for
inflammation-mediated applications.
While the direct mechanism of NF-κB, JNK and ERK pathway suppression is not
known, it is theorized that flavonoids can inhibit transcription by preventing complete
phosphorylation of the protein portions required for activation [41, 42]. However, as noted
by quercetin’s ability to only suppress JNK pathways [35, 43], and apigenin’s ability to
suppress JNK and ERK [37, 44], it becomes clear that antioxidant activity alone cannot
explain the anti-inflammatory function.
Because of the limitations of poly(trolox) ester in the inability to control degradation
rates outside of molecular weight synthesis [22, 45], and inability of vitamin E to suppress
certain inflammatory pathways [40], it is desirable to develop a new antioxidant polymer
system that is based on a biologically active flavone PβAE nanoparticle system, that can
also be modified through the use of targeting moieties in the future.
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In this work, we first evaluate the ability of poly(trolox) to suppress clinically relevant
injury and diseases, followed by the development of an anti-inflammatory polymer with
desirable long term release properties. We have modified existing poly(trolox)
nanoparticles to target specifically to vascular tissue through the use of monoclonal
antibodies directed towards PECAM-1. We show that these particles can adhere to the
endothelium, internalize, and suppress toxicity and free radical damage caused by iron
oxide nanoparticles. Next, we utilized a similar nanoparticle system of poly(trolox) to treat
the damaging effects of rheumatoid arthritis in vivo. Our results indicate that these particles
are small enough to accumulate in disrupted vasculature, recover natural antioxidant
capacity, and inhibit certain inflammatory markers such as TNF-α and IL-6. In the last set
of work, we have developed an anti-inflammatory system comprised of our unique
poly(beta-amino ester) chemistry to deliver the compound apigenin over an extended
period of time. It was observed that particles comprised of apigenin PβAE released active
apigenin over 72 hours, and were able to inhibit the ability of tumor cells to adhere and
metastasize in compromised vascular cells. It was found that this was due to the significant
suppression of inflammation markers provided by the apigenin, further reinforcing the link
between cancer metastasis and inflammation.
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Chapter 2. Background
Based on the book chapter published in:
David Cochran and T. Dziubla. “Antioxidant Polymers for Tuning Biomaterial
Biocompatibility: From Drug Delivery to Tissue Engineering”, In G. Cirillo, Antioxidant
Polymers Synthesis, Properties, and Applications. Salem, MA: Scrivener

2.1 Introduction
While the original definition of a biocompatible material was one that does not induce
deleterious effects (e.g., a host immune response[46]), it has become clear that definition
no longer fits with the advanced biomaterials designs. As our fundamental understanding
of biological responses to foreign material increased, so did our knowledge that a purely
inert material was both unfeasible and in some instances, especially in the area of tissue
regeneration, undesired. A classic example is in the case of titanium oxide. While titanium
oxide in a bulk phase has traditionally been utilized as an inert coating of implants, it has
been found that wear particles in the nanometer size range can elicit a strong oxidative
insult [47, 48]. Because of this, a new definition of biocompatibility has been proposed by
D.F. Williams that a biomaterial must perform not only its function without undesired
consequences, but also generate a beneficial tissue or cellular response [49]. Indeed, this
shift in paradigm has not only challenged the “biocompatibility” of classical materials,
but also paved the way into development of new and exciting methods to develop a material
that can induce a beneficial host response.
2.2 Oxidative stress
Reactive oxygen and nitric species (ROS / RNS) are formed and utilized by all
aerobic organisms [50]. As such, ROS/RNS are not inherently undesired as they
participate in the key role of cell signaling and activation pathways [51, 52]. This is done
5

by direct oxidation of residues on proteins [53], degradation of inhibitory proteins [54],
regulating immune system function to attack pathogens [55], or even signaling of
differentiation or apoptosis [56, 57]. It is when reactive species production overtakes
natural antioxidant capacity that oxidative stress is said to occur [18]. This unbalance
leads to uncontrolled degradation which can lead to cellular dysfunction and death [58,
59]. Additionally, oxidative stress has been implicated in numerous diseases and
conditions, such as tumor pathogenesis [60], systemic inflammation [61], COPD [62],
and even aging [11].
2.3 Mechanisms of oxidative stress
Although the term “reactive oxygen species” (ROS) is most commonly used when
describing oxidative stress, it is important to note that oxygen-based species are not the
only contribution to stress. Nitric species, such as nitric oxide (NO·) and peroxynitrite
(ONOO-) play a just as important role in the cascade of signaling and injury [59, 63].
Superoxide (O2·-) is the species most often implicated in the initiation of oxidative
stress [64, 65]. It can be formed in the presence of the electron-rich environment of the
mitochondrial membrane in the respiratory chain [66]. In addition it can be produced
endogenously by multiple enzymes. Xanthine-oxidase, which is typically activated and
expressed in ischemia-reperfusion injury [67, 68] is one source. Another major source of
enzyme-derived superoxide generation is the NADPH-oxidase pathway. NADPH-oxidase
is a membrane-bound complex that facilitates superoxide production as a means to inhibit
and destroy pathogens [69]. While two molecules of superoxide can dismutate
spontaneously, endogenous superoxide dismutase (SOD) significantly speeds up this
reaction.
6

Hydrogen peroxide, while not a free radical in itself, does function as a radical
intermediate. It is an important compound because of its ability to penetrate and diffuse
across cellular membranes [70]. Hydrogen peroxide can be reduced to hypochlorous acid
through myeloperoxidases [71], or into hydroxyl radicals through iron reactions via
Fenton chemistry [72].
The hydroxyl radical (·OH) is perhaps the most damaging radical to biological
systems [73, 74]. It is produced from multiple sources. Hydrogen peroxide can react with
metal irons to form hydroxyl radicals, otherwise known as Fenton chemistry [75]. These
radicals can react with unsaturated fatty acids to form lipid radicals, which in turn form
lipid hydroperoxides. Lipid hydroperoxide can once again undergo Fenton chemistry,
leading to a propagating cycle of lipid oxidation and destruction [76, 77]. In order to
combat the potential damage hydroxyl radicals can inflict, cellular defense systems
consist of glutathione, a tripeptide which functions as a cellular antioxidant [78].
Table 2-1 outlines the common free radicals, their sources, and the accompanying
cellular defense systems.
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Table 2-1. Reactive Molecules and Their Sources

Reactive Molecule

Source

Cellular Defense
Mechanisms

Referenc
es

Hydrogen peroxide
(H2O2)

Glucose oxidase
NADPH-oxidase
Superoxide dismutase
P450 reductase
Xanthine oxidase

Catalase
Glutathione peroxidase
Myeloperoxidase

[79]

Hydroxyl (·OH)

Fenton chemistry
H202 degradation

Glutathione

[80]

Nitric Oxide (NO)

Nitric oxide synthase

Glutathione

[81]

Peroxynitrile
(ONOO·)

Reaction with nitric
oxide

Superoxide (O2·-)

Electron transport
chain
Cyclooxygenase
NADPH-oxidase
Xanthine Oxidase

8

[82]

Superoxide Dismutase

[83]

2.4 Oxidative stress in relation to biocompatibility
Oxidative stress occurs when a cell’s inherit antioxidant capacity is exceeded by the
production of reactive species. Oxidative stress has been identified as a key pathological
process in many disease states[1, 84]. This effect has been attributed to the ability of
reactive oxygen and reactive nitrogen species (ROS and NOS) to induce oxidation of
protein backbones [85, 86], amino acid residues[87], and ultimately to fragmentation of
essential proteins in a cell. Accumulation of this oxidized protein has been associated with
disease and inflammation [54, 87]. DNA damage associated with fragmented protein base
pairs, along with lipid peroxidation can also result in symptoms of cell cycle arrest,
depleted antioxidant defense capability, mutations, etc. [88]. The clinical impacts can
include carcinogenesis, neurodegeneration, and inflammation/infection. Importantly here,
oxidative stress has been shown to play a pivotal role in biomaterial biocompatibility. This
connection is best demonstrated through a discussion of the relationship between oxidative
stress and inflammation, which will be detailed below.
2.5 Mechanism of immune response
The immune system response is classically separated into two distinct pathways,
inflammatory response and adaptive immunity. The inflammatory response confers an
immediate and non-specific defense against pathogens, injury, and foreign materials[89].
When a foreign body enters the body (or in our case, a biomaterial is implanted) the natural
immune response begins with blood-material protein adsorption, cellular activation and
macrophage recruitment, followed finally by fibrous capsule formation [90]. Table 2-2
illustrates the processes involved in the inflammation pathway. Biomaterial failure can
occur at any one of these steps. For example, urethane coatings on silicone implants have
9

been observed to degrade over time, inducing localized oxidative stress. The result of this
elicits fibrous encapsulation, which can lead to further complications requiring removal of
implants, or permanent scarring[91]. Another non-classical example of biomaterials failure
are drug loaded nanoparticles, which can be quickly cleared from the body due to bloodmaterial interactions, known as opsonization.
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Table 2-2. Summary of the biomaterial induced inflammatory response

Inflammation
Characterized By
Stage

11

Role of Oxidative Stress

Example of Failure of Biomaterials in
this Stage

Opsonization

Foreign material bound by
complement molecules
(antibodies, etc.). Bound
compliments trigger immune
defense via WBC recruitment and
macrophage activation

Free radicals have shown to initiate
compliment pathways (classical,
alternative, lectin), leading to
cellular activation

Therapeutic nanoparticle systems (PEG,
PLGA, etc.) have the potential to be
opsonized and quickly cleared [40]

Cellular
Activation

Recruitment and activation of
macrophages and other
monocytes. Tissues increasing
expression of chemoattractants
such as MIP-1, MCP-1, and CSF1

Oxidative species play a role in
inducing the secretion of other
chemokines, as well as possessing
the ability to activate circulating
immune cells such as leukocytes

Monocyte activation leads to respiratory
burst. High concentrations of localized
acidic and oxidative environments have
been shown to inactivate peptide and
proteins[41]

Macrophage
Recruitment
and Adhesion

Adhesion of macrophages to an
implant or injury surface.
Chemokine expression recruits
circulating macrophages. Adhered
macrophages begin to initiate
oxidative bursts to destroy foreign
material

Generation of superoxide to destroy
invaders. Surrounding tissue can be
affected and become inflamed in the
process

Continual oxidative burst can propagate
stress cracks of implants [35] or premature
oxidation of metal compounds (such as
electrical leads in pacemakers) [36]

Fibrous
Encapsulation

Macrophage fusion and full
encapsulation of implant. Chronic
inflammation and pain

Oxidative species have been shown
to trigger macrophage fusion.
Chronic inflammation due to
elevated levels of reactive species
and reduced GSH.

Implant loosening due to fibrous
encapsulation [37]. Therapeutic
inactivation of controlled release devices
due to diffusional barriers

When injected materials, especially free circulating, high surface area particles, are
introduced into the blood stream opsonin proteins can adhere to their surfaces, mediating
a phagocytic clearance response [92]. This can directly lead to loss of therapeutic efficacy,
a failure of the biomaterial intended function.
A central component of the inflammatory response is the induction of oxidative stress.
In most scenarios, a material’s biocompatibility is most tested during the inflammatory
phase of healing, which ultimately dictates the foreign body response and degree of fibrous
encapsulation. Upon interaction with blood and plasma exudate, a layer of host proteins
interact with and adhere to the surface of the biomaterial [93]. The chemistry and physical
conformation of the surface play a crucial role in the type of protein adsorbed [94, 95].
Tegoulia et al. reported that protein adsorption was highest in hydrophobic and polar
surfaces, whereas leukocyte adhesion was highest on phosphorylcholine rich surfaces[94].
In addition, depending on the surface, these proteins may desorb rapidly, leading to timedependent delays in activation of the immune response, known as the Vroman effect [96].
Preliminary data has suggested this effect could be responsible for cases of patterned
thrombus formation in artificial organs and vasculature applications [97].
The presence of these accumulated proteins, which include compounds such as
fibrinogen, vitronectin, fibronectin, and other globulin proteins [98], initiate the process of
thrombosis. Activated blood platelets and clotting factors stimulate the production of
chemo attractants, such as platelet-derived growth factor (PDGR), transforming growth
factor (TGF), and cytokines such as interleukins and leukotrienes [99]. These signaling
molecules serve to attract many types of phagocytes (monocytes, macrophages,
neutrophils, etc.) to the site of accumulation. Macrophages, in particular, begin to excrete
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their own chemo attractants, initiating an immunological recruitment cascade. In addition,
localized inflammatory neutrophils begin to attack both foreign material and
microorganisms through secretion of oxidative species[100]. These oxidative species play
a role in inducing the secretion of other chemokines, as well as possessing the ability to
activate circulating immune cells [101]. This cyclic process of recruitment, activation, and
stress leads to a propagation of injury and disease states.
Oxidative stress also plays a crucial role in the recruitment of other inflammation cells
through the process of chemotaxis. Leukocytes can respond to H2O2 gradients, NADPHox
activation, and LPS stimulation [102, 103]. When these cells identify a foreign body or
unknown pathogen, their response is to initiate an oxidative respiratory burst of superoxide
and hydrogen peroxide[104]. This burst of ROS and RNS is utilized to destroy the invading
material. While inflammatory cells can protect themselves through increased uptake of
glutathione [105], vascular tissue cannot. This leads to a cascading loop of increased
oxidative stress in tissue, which stimulates chemotaxis recruitment of more inflammatory
cells.
Following the initial phase of inflammation, macrophages can internalize the activated
and apoptotic neutrophils and subsequently clear them from the injury site. In the case of
implanted materials, these macrophages can adhere to the protein coated implant surface
and initiate the foreign body response reaction[17]. Adhered macrophages are able to
further fuse together to form foreign body giant cells. While the exact signaling required
to initiate this cascade is currently unknown, it has been shown that IL-4 and IL-13 [106108] along with mannose play critical roles in expression of the required adhesion
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molecules to elicit macrophage fusion. These adhered macrophages and foreign body giant
cells can subsequently interfere with the intended function of the biomaterial in question.
It becomes obvious that oxidative stress plays an important role throughout all steps in
the immune response to foreign or implanted material. The following section shall present
some examples of this oxidative stress driven failure of biomaterials.
2.6 Examples in practice
One of the most widely used implant polymers is polyurethane (PU) based. PUs have
been utilized in applications such as valve replacements, vascular grafts and stent
coverings, and in coatings of silicone breast implants [109]. While PU based polymers
typically have ideal mechanical properties and show reasonable blood-material
compatibility, it was discovered that long-term stability in tissue was a problem when in
contact with vascular tissue. This launched a long reaching investigation into methods of
in vivo biodegradation in the late 1980’s [110]. Aliphatic esters were observed to be
hydrolytically degrading in polyester-urethane systems [111]. In polyether-urethane
systems, commonly incorporated in breast implants and valve replacements, a phenomenon
of micro-fissure formation was seen, termed environmental stress cracking. This
phenomenon occurred whether the implant was subjected to intense mechanical stress or
not. Further research concluded that ROS produced from adhered macrophages and foreign
body giant cells began to degrade and corrode the system. This effect was even greater
when metal compounds were incorporated in the urethane device [111, 112], such as in the
case of coated implanted pacemaker leads.
Besides PU cracking, aseptic loosening of orthopedic implants can also be a result of
oxidative stress. Total hip arthroplasty is especially susceptible to dislodging and failure.
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It has been theorized that a combination of mechanical wear, increased intraarticular
pressure due to fibrous encapsulation, and high oxidative stress contributing to localized
septic tissue, contribute to premature failure of hip implants [113-115]. Supporting this
theory, groups have looked into the involvement of free radicals in localized fibrous tissue
around implants. Kinov et al. examined tissues obtained directly from patients with both
loosened implants and structurally sound implants. From these tissue samples, the group
looked at GSH/GSSH ratios, malondialdehyde, and collagen formation [113].
The results indicated a substantial increase in depleted GSH, lipid oxidation, and
excessive collagen formation, all indicative of oxidative stress and overproduction of free
radicals, in samples from patients with loosened implants, as compared to both intact
implants and controls. FIGURE 1 illustrates a hypothesized model of ROS interaction and
fibrous formation.
Besides permanent implants, biodegradable materials can also induce an oxidative
stress related inflammatory response. Poly lactic co-glycolic acid (PLGA) has been
investigated for its particle formulation capacity, and was perceived as being
biocompatible, as its degradation products of lactic and glycolic acid are both naturally
found in tissue. Yet, it was found that due to slow hydrolysis and high concentration of
localized acidic degradation products, compared to what naturally occurs in tissue [116],
PLGA has limited use in clinical applications. Springer et al. had investigated the
inflammatory response of PLGA nanoparticles administered to the lungs of rats. The group
observed a marked influx of both macrophages and neutrophils into the lung tissue of
treated rats [117]. The macrophages had demonstrated the ability to engulf these PLGA
particles; however a 40 day half-life of these particle dosages was measured. In addition,

15

localized areas of acidic environments were measured, which can potentially interfere with
drug delivery methods utilizing protein and peptides [118]. Other groups have also
demonstrated increases in oxidative stress, via lipid peroxidation and GSH/GSSH assays,
with respect to degradation of the polymer.
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Figure 2-1. A hypothetical model illustrating the mechanism of ROS and implant
inflammation
Either mechanical or chemical insults can result in the generation of ROS release. This is
either directly from the degradation products, or as a secondary result of the activation of
neighboring cells. The release of ROS induces macrophage recruitment and activation.
These activated macrophages can also release ROS, further stimulating localized oxidative
stress and inflammation. This ROS release also results in potential degradation, mechanical
wear and stress cracking of the implant. These responses can all lead to additional oxidative
stress, further stimulating localized inflammation. Prolonged effects could lead to fibrosis,
implant morbidity and loosening of the implant. MF=Macrophage, ROS = Reactive
Oxygen Species.

17

This indicates that classically biocompatible materials, when subjected to biological
conditions, can elicit a relevant host response through the generation of oxidative stress.
2.7 Antioxidant polymers in drug delivery
The relationship between oxidative stress and many diseases, such as Alzheimer’s
[119] and Parkinson’s disease [120], is well documented. And while it stands to reason that
antioxidant therapy should provide an effective treatment strategy for these diseases, there
exist many limitations, which have prevented their wide scale use. Indeed, conflicting
results from many studies confound the beneficial effects of orally delivered antioxidants
[121-123]. Direct application or injection of pure antioxidants at the site of interest is also
plagued by rapid clearance and nonspecific distribution. Antioxidant polymers are a
promising solution to delivering antioxidants, potentially overcoming these problems.
Further, antioxidant polymers may also provide supportive benefits to other therapeutic
strategies. The following outlines both of these approaches.
2.8 Uses as active pharmaceutical ingredients
Most obviously, antioxidant polymers can be used as a therapeutic alternative to small
molecule antioxidants. For instance, trolox, a water soluble analogue of vitamin E, is
known to have extensive antioxidant activity. Indeed, trolox is commonly used as a
reference standard for total antioxidant potential [124]. Yet, trolox has not seen direct
clinical success due to its poor biodistribution and local accumulation.

Recently,

Poly(trolox) polymers were synthesized, where were demonstrated to undergo enzymatic
degradation to release monomers of active trolox. This hydrophobic polymer was
formulated into nanoparticles, demonstrating the ability to suppress oxidative damage
caused by metal nanoparticle toxicity in vitro [22]. Similarly, these antioxidant
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nanoparticles also have mitigated the oxidative damage caused by hydrogen peroxide and
iron oxide and recovered cellular viability. Perhaps most interestingly about this polymer
is not its ability to degrade, nor reduced toxicity attributed to its “polymer” characteristics,
but that it possessed the ability to suppress protein carbonyl formation. Overall protein
carbonyl and 3-NT levels were suppressed, markers of overall protein damage and damage
via RNS respectively. This level of protection was not seen in free trolox, suggesting the
route of delivery plays a very important role in therapeutic benefits [45].
Dziubla et. al have also developed a class of poly(beta amino ester) polymers with
incorporated phenolic antioxidants such as quercetin and curcumin. Selection of the
monomers in formulation gives extensive control over degradation, and subsequent
antioxidant release, times via hydrolysis. These polymers have been shown to modulate
the oxidative state in vitro cell culture models and provide protection against oxidative
stress insults, similar to poly(trolox). Some of the advantages provided by this polymer
chemistry are that it does not require free-radical polymerization, thereby allowing loading
of antioxidant drugs that are susceptible to free-radical damage. In addition, the availability
of a large library of commercial diacrylates [125, 126] could be used to tune polymer
properties, and that it could be extended to any class of polyphenolic antioxidants. The
toxicity profiles observed with the polymers were similar to that of the pure antioxidant,
indicating toxicity and activity were functions of the loaded therapeutic content, rather than
constituent compounds in the polymer.
Puoci et al. developed a one-step reaction by free radical polymerization to form a
PMMA-ferulic acid copolymer. The polymer showed high scavenging activity, with little
interference of activity from the PMMA backbone [127]. Application of this material
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shows promise in hemodialysis, cosmetic stability, and as preservative agents in food. With
the ability to develop limitless classes of high molecular weight antioxidant polymers that
exhibit increased stability, decreased toxicity, and tunable delivery rates [45, 128, 129],
many of the traditional obstacles involved in direct antioxidant drug delivery can
potentially be overcome.
2.9 Uses as pharmaceutical excipients
While developing treatment strategies, it is important to keep in mind that the shelf life
and stability of drug formulations are essential in the practical applications of therapeutic
systems. The potential for oxidation and decreased efficacy can be seen in both initial
formulation, as well as in long term storage. The protection and longevity provided by
antioxidant polymers presents an excellent opportunity to increase a biomaterials window
of use, even before introduction into the body.
With the increased production (and expense) of protein based therapies such as
monoclonal antibodies, hormones, and interleukins, developing methods to increase the
shelf life of these compounds has become extremely important. A major pathway of
degradation has been identified as oxidation of methionine [130-132]. Strategies to
overcome this stability problem have been the addition of chelating agents, chain
terminators, or small molecule antioxidants. Common materials utilized are free
methionine or sodium thiosulfate [133]. Experiments have shown increased stability of
aqueous and lyophilized formulations up to two weeks in dark ambient storage conditions
[134] with little loss in activity shown in Figure 2-2.
Expanding on the idea of utilizing slow degrading antioxidant polymers Davis et al.
developed a system of carbohydrate-antioxidant (vitamin E) hybrid polymers for prolonged
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protection from oxidation in applications of both storage and active delivery of
spermatozoa. Their results reported a significant increase in sperm activity utilizing a
controllable antioxidant delivery system over time compared to addition of free vitamin E
during storage. Additionally, they also saw up to a 20 fold increase of sperm delivery in
vivo compared to control systems. It was theorized that the protective polymer system was
able to protect spermatozoa during the uptake and intracellular trafficking, whereas free
vitamin E was quickly leached out and lost during endosome activity [135].
Antioxidant polymers also have applications in long term preserving and prevention of
oxidative stress cracking in implant based biomaterials during formulation and storage,
which will be discussed in a later section.
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Figure 2-2. Effect of antioxidants on light-induced oxidation of rhuMAb HER2
formulation
Antioxidants were added to the formulation before filling into sample vials. Sample
containing no antioxidant (black), 6.3 mM sodium thiosulfate (gray), and 3.5 mM
methionine (striped) were stored wrapped (Dark) and unwrapped (Light) in a light box with
light intensity of 20 000 lux for 2 weeks. The light box temperature was 27 °C. After light
exposure, samples were assessed for methionine oxidation of rhuMAb HER2 by HIC.
Results were also compared with the control samples stored in the dark at 5 °C for 2 week.
(Figure reproduced from [134])
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2.10

Antioxidant polymers in anti-cancer therapies

In addition to direct lipid and DNA damage caused by oxidative stress, endothelial cells
can produce cytokines and chemokines that play a role in propagation of the inflammatory
response [136] such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor
alpha (TNF-α) [9, 137]. This inflammatory response can, in turn, induce signal activation
of the NF-кB pathway, initiating a cascade of gene activation to regulate antioxidant and
immune defenses [138]. Endothelial cells, in response to this pathway activation, begin to
secrete and express molecules known as Cellular Adhesion Molecules (CAM) on their
surfaces to facilitate leukocyte adhesion, vasodilatation, and transmigration [14].
In recent years, researchers have focused on the cellular mechanisms of tumor cell
extravasation and transmigration to other organs and tissues. It has been hypothesized that
circulating tumor cells develop cellular adhesion molecule binding ligands specific for Eselectin[139, 140], ICAM-1 [42], and VCAM-1 [42]. Circulating tumor cells of many
different origins [141] have been shown to utilize inflammatory response CAMs for
adhesion and invasion into downstream vascular beds. Similarly, groups have shown that
oxidative stress generation in cell culture experiments through injury agents such as H2O2
or TNF-α stimulation can directly stimulate expression of these CAMs, and subsequent
studies have shown that circulating tumor cells can firmly adhere to endothelial cells grown
in flow culture systems that have been activated by these injury agents, as compared to
non-stimulated cells [141]. These results indicate a relationship between oxidative stress
generation and cancer formation, either by cytokine stimulation (TNF-α, IL-8, etc.), or
supplemental ROS induction (smoking, UV exposure, ionizing radiation). In addition, it
has been shown that addition of monoclonal antibodies directed towards E-selectin, ICAM-
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1, and VCAM-1 to block current expression in activated endothelial cells can significantly
attenuate tumor cell adhesion [141, 142].
New research however has delved into how certain classes of antioxidants modulate
cellular responses and pathway activation or deactivation. It has been observed that
flavonoids such as quercetin, epicatechin, and curcumin not only reduce oxidative stress,
but can suppress inflammatory pathways such as NF-κB and AP-1 through inhibition of
specific kinase pathways [35-37]. Interestingly, quercetin is the only reported flavanol with
the ability to suppress both ICAM-1 expression and NF-κB activation through JNK
pathway inhibition [35]. Flavones on the other hand, have been reported to suppress JNK
and ERK pathways, leading to down regulation of ICAM-1, VCAM-1, and E-selectin,
along with NF-κB [36], making them great candidates for applications such as cancer
metastasis prevention. While the direct mechanism of NF-κB, JNK and ERK pathway
suppression is not known, it is theorized that that flavonoids can inhibit transcription by
preventing complete phosphorylation of the protein portions required for activation.
Recently, the anti-proliferative effects of curcumin have been of notable interest, owing
to its selective cytotoxicity to cancer cell lines, it’s antioxidant activity, and low toxicity in
vivo [143, 144]. Unfortunately, curcumin exhibits poor water solubility and has a
therapeutic half-life of under 15 minutes at pH 7.4 [145]. To this end, Tang et al. developed
a system of polycurcumins with a range of molecular weights, degradation times, and
solubility. One system, labeled PCurc8, was found to be both water soluble and exhibit
higher stability than pure curcumin. In vitro it was shown to be more cytotoxic by mass
than pure curcumin, along with arresting division phases of tumor cells FIGURE 3. In vivo,

24

the easily formulated and injectable system showed remarkable antitumor activity in a
xenograph model [146].
This shows promises that direct antioxidant therapy as a biomaterial in of itself, which have
demonstrated suppression of these CAMs, can be utilized as a treatment for prevention of
tumor formation.
2.11

Antioxidant polymers in wound healing and tissue engineering

In the previous sections the direct and indirect ways oxidative stress plays a role in
relation to biomaterial function have been discussed. Free radicals can directly damage a
biomaterial, such as in the case of polyurethane coatings and hip implants. Indirect methods
of failure can occur such as the degradation of newer generation materials, previously
believed to be biocompatible. The following section reviews potential applications of
antioxidant polymers to address both these direct and indirect stress mechanisms.
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Figure 2-3. Cytotoxicity of PCurc 8 to SKOV-3, OVCAR-3 and MCF-7 cancer cell
lines
Cells were treated with PCurc 8 for 72 h followed by 24 h incubation in free medium.
(Figure reproduced from [146])
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2.12

Antioxidant polymers incorporated into biomaterials

Recently, groups have attempted to mitigate the oxidative stress induced from
biomaterial implantations. Initially, research was focused into developing biomaterial
platforms that have a neutral host response, such as systems with PEG coatings, or
degradable platforms utilizing polyketals[147]. Others have modified existing material
selections to incorporate small molecule antioxidants or even enzymatic antioxidants.
Strategies to incorporate antioxidants into existing scaffolds or hydrogels have also proven
effective in creating artificial diffusion barriers, simulating the effects of a degradable
antioxidant polymer system [148]. Initial work with these methods of antioxidant grafting
or loading has proven effective in vivo.
2.13

Direct prevention of implant failure

Within the past five years, focus has shifted towards prevention of aseptic loosening of
implanted materials through the use of antioxidants to mediate damage caused by extensive
wear and particulate formation over time. Initially research focused on elimination of
oxidized material during creation of the implant[149] using methods such as inert gas
irradiation. Even though these methods improved material shelf life, a growing amount of
evidence supported the oxidation stress in vivo hypothesis. Stemming from this
information, a second generation class of implants was developed utilizing antioxidant
stabilizing compounds, such as Vitamin E. Vitamin E is typically added in low
concentrations during consolidation of the ethylene polymer. Clinical data suggests
blended formulations with concentrations less than 0.1% vitamin E maintain the same
physical and mechanical properties [150] and can prevention of oxidation up to 24 months
post implantation [151]. In addition, preliminary in vitro and in vivo data using particulate
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matter from antioxidant loaded implants indicates a reduction of phagocyte adhesion and
activity [152]. Promising results stemming from these initial studies provide a framework
for the incorporation of long lasting antioxidant polymers to provide protection over
extended periods of biomaterial use. One can also imagine with classes of antioxidant
materials exhibiting high mechanical loading capabilities, that higher antioxidant content
can theoretically be incorporated into implants as well.
Another example of utilizing antioxidant polymers to improve biocompatibility is in
the area of ophthalmology. Cirillo et al. reported on the ability to graft quercetin, a potent
flavonoid, into traditional pHEMA hydrogels used in contact lenses through free radical
grafting reactions discussed earlier. Quercetin was selected owing to its anti-inflammatory
properties and ability to prevent cataract formation in preliminary in vitro models. Contact
lenses have the potential to induce ocular damage by interrupting the ability of the
epithelium to absorb oxygen from the atmosphere [153]. Similarly, UV radiation can
propagate the formation of free radicals, which can compound the oxidative stress effect
from restriction of oxygen supply to the eye. The results of this study indicated that the
Quercetin-HEMA gels exhibited significant antioxidant activity, and an irritancy index of
zero, meaning high compatibility and no signs of irritant effects in a chicken embryo
chorioallantoic membrane (CAM) model [154] as opposed to unmodified HEMA lenses,
which scored an irritancy index of 1 (mild irritant effects, good compatibility). This
application of grafting antioxidants into externally applied biomaterials can begin to pave
the way to suppressing the damage associated with ocular irritation. Simultaneously, the
delivery of quercetin directly to ocular epithelium can help treat existing diseases such as
cataracts and glaucoma.
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2.14

Mitigation of toxic side effects

While antioxidants show promise in the ability to prevent modes of failure in
biomaterial implants such as joint replacements and contacts, it is also important to delve
into the ability of these antioxidants to mitigate the eventual damage caused by the
degradation of newer classes of biomaterials. In the recent years, many newer generations
of materials have been developed with the premise to degrade over time, allowing the
body’s own wound healing process to coincide with deterioration and infiltrate through the
material. Implant systems once thought to be “biocompatible” such as TEGDMA,
commonly used as inert coatings on dental implants, PEG, considered the gold standard in
immune system masking, and PLA/PLGA, a naturally derived copolymer from lactic and
glycolic acid, have all been shown to induce oxidative stress over time (TEGDMA,
PLA/PLGA)[155, 156], or elicit a host immune response in the form of antibody synthesis
(PEG) [157].
With the advent of these discoveries, it became clear that when developing new classes
of biomaterials the entire lifetime of the implant must be taken into account. This not only
includes response upon implantation but also during its degradation time. Because of the
oxidative nature of these end products, grafting, or blending, antioxidant polymers into the
material is an ideal strategy for mitigating this potential damage.
One example is that of dental composites containing HEMA and TEGDMA. These two
polymers are an attractive alternative to typical amalgam and gold in classical fillings.
Within the past 5 years, implants have shifted to approximately 50% by weight of newer
HEMA/TEGDMA bonding resins [158]. It has been shown that as the resin deteriorates
from normal wear and tear, particulate matter can lodge in the lung epithelium, and
29

inducing oxidative stress mediated damage. In cell culture models, particulate matter
cultured with human pulp and gingival fibroblasts was associated with depleted GSH and
eventual cell apoptosis [159, 160]. Schweikl et al. investigated the effect of increased
oxidative stress of both compounds. It was discovered that concentrations of 1 mmol/L in
V79 fibroblast cells induced substantial genotoxic effects. Cell cycle disruption was
observed, along with significant micronuclei formation, both indications of genotoxic
effects. They hypothesized this was due to oxidative stress, and examined the effect of Nacetyl cysteine (NAC) would have on the same cell model. The results demonstrated that
concentrations of 10 mmol/L of NAC significantly decreased the micronuclei formation
resulting from both HEMA and TEGDMA treatments [161]. This work has set a
fundamental basis into the application of antioxidants in vivo may be a viable strategy to
reduce toxic side effects, and increasing overall biocompatibility.
Another example of polymeric materials utilized to suppress toxic side effect is to
utilize enzymatic antioxidants or mimetic. By covalently conjugating super oxide
dismutase mimetic (SODm) to the backbone of UHMWPE and PU polymers, a new
platform for biomaterial structures was created. These SODm grafted polymers showed
potent acute and chronic anti-inflammatory properties in vivo. Rat implants showed
inhibition of neutrophil infiltration over 3 days. Extended out to 28 days, there was a
significant suppression of foreign body giant cells and fibrous encapsulation [162]. Figure
2-4 illustrates the cell count and capsule thickness as a function of SODm conjugation.
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Figure 2-4. Effect of SODm grafting on polymer implants
Graph of FBGCs counts (left) and capsule thickness (right) for control and SODm-treated
PE implants at 28 days. (Figure reproduced from [162])
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2.15

Stimulation of direct wound healing

In addition to the utilization of antioxidants and antioxidant polymers in biomaterial
implants, antioxidants as a direct delivery agent have been shown to possess properties to
enhance the body’s ability to heal itself. This has obvious advantages in enhancing
recovery time from surgical wounds or injury unrelated to biomaterial insertion.
Previously groups have shown that incorporation of natural antioxidants, such as
quercetin and curcumin, into 3D hydrogel scaffolds had successfully improved the wound
healing response to deliberate dermal injury. The antioxidant loaded scaffolds showed
reduction in healing time and dramatically reduced scarring formation [163, 164].
Similarly, carbodymethylcellulose (CMC) gels with entrapped SOD showed similar effects
both in vitro and in vivo [165].
2.16

Conclusions and perspectives

In conclusion, it has become apparent that there are nearly limitless strategies for
developing new and novel antioxidants for clinical applications. Table 2-3 consolidates a
list of antioxidant polymers and their applications. Additionally, as our knowledge expands
on the effects of oxidative stress and how they relate to diseases, so to do our options for
utilizing antioxidants in our current treatment strategies, either as direct therapies or in
tandem with other biomaterials. By controlling the level and time of delivery through new
chemistries and systems, modulating the oxidative state of the body can be accomplished,
allowing for greater flexibility and treatment windows in traditional biomaterials. While
clinical data and application at this time has been limited due to unknown factors or
mechanisms of antioxidant function, the consistently positive results obtained from
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ongoing in vivo trails will begin to pave the way into a new future of medicine and
applications.
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Table 2-3: Antioxidant polymers and their applications
Polymer
Structure
/Backbone

Functional
Antioxidant

Administration
Method

Application

Mechanism of Action

Ref

Carbohydrateantioxidant
hybrid
polymer

α-tocopherol

Mixed in
Seminal Fluid

Prolong functional viability and
fertility rates of mammalian
spermatozoa

Specific uptake of carbohydrate
polymer in sperm prevents
oxidative damage during storage.

[135]

Nanoparticles

Slow release of trolox through
degradation has potential in controlling
cell status in biomedical and tissue
engineering applications

Poly(Trolox) suppresses oxidative
stress levels in cells. In addition,
polymeric form has shown to
reduce protein carbonyl levels, a
feature not seen in free trolox

[45]

Water
solubilized

Demonstrated high superoxide
scavenging ability and inhibition of
LDL oxidation

Antioxidant capability more potent
in polymer form. Increased
superoxide scavenging along with
prevention of cellular damage

[128]

SOD reduces superoxide at the
biomaterial interface, inhibiting
macrophage activation and
neutrophil infiltration

[162]

Active quercetin mitigates
oxidative stress damage caused by
oxygen deficiency due to contact
lens barrier

[154]

Poly(Trolox)

Trolox

34
Poly(Rutin)

Rutin

UHMWPE

Superoxide
Dismutase
Mimic

Implantable Gel

Significant suppression of
inflammatory response along with long
term inhibition of fibrous
encapsulation

Quercetin

Implantable
Hydrogel

Contact lenses formed using quercetinHEMA exhibit irritancy index of zero

HEMA

Chapter 3. Research Goals
3.1 Introduction
In this body of work, we have developed antioxidant and antiinflammatory delivery systems to be used in practical applications, such as the treatment
of cancer and arthritis. These delivery devices are in the form of nanoparticles that can be
modified to target cell types of interest, or provide long circulation times due to the
stealth enhancing properties of PEGylation. We have shown that the antioxidant systems
can inhibit free radical damage and restore cellular viability in vivo. Additionally we
have demonstrated that these particles of poly(trolox) can be utilized in vivo to reduce
cytokine levels associated with oxidative stress, and prevent protein oxidation. This is a
unique feature not observed in the native form of trolox, conferring an additional level of
protection for future studies.
In a similar fashion, our anti-inflammatory particles can suppress the expression of
inflammatory markers on the surface of vascular cells, which circulating tumor cells can
utilize to attach to the vascular bed. The long term release provided by these polymer
nanoparticles can prevent tumor cells from adhering for up to 72 hours, coinciding with
the natural inflammation response cascade.
3.2

Objectives and Significance

The overall hypothesis of this work is:
Antioxidant and anti-inflammatory polymer systems can be utilized to treat a
variety of clinically relevant injuries through the suppression of oxidative stress
and inflammation.
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In order to test this hypothesis, three stages of research were planned. Each stage is
described in detail below:
3.2.1

Specific Aim 1: Utilization of targeted antioxidant nanoparticles to inhibit
iron oxide nanoparticle injury

A. Development of poly(trolox) nanoparticles with a functional antibody coating
specific towards PECAM-1, a constitutively expressed protein on the surface of
endothelial cells.
B. Quantification of particle specificity, internalization potential, and antioxidant
capacity in an endothelial cell culture model.
C. Utilize targeted poly(trolox) nanoparticles to inhibit the toxicity associated with
iron oxide nanoparticles.
3.2.1.1

Hypothesis #1
Poly(trolox) nanoparticles can be modified to actively target vascular cells to
suppress the oxidative injury from iron oxide nanoparticle accumulation.

3.2.1.2

Significance and Outcome

Chapter 4 highlights the experiments used to test our hypothesis. Poly(trolox)
nanoparticles were successfully synthesized using a solvent in solvent nanoprecipitation
technique. These particles were then coupled with a targeting antibody directed towards
PECAM-1. These nanoparticles adhered to vascular cells, internalized, and significantly
reduced background oxidative stress. We then determined the therapeutic efficacy of
targeted PTx in an iron oxide nanoparticle injury model. It was found that we could not
only inhibit oxidative stress, but also recover cellular viability. This result demonstrates
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the ability to not only target nanoparticles to sites of interest, but reveals that antioxidant
therapy can be a viable treatment option to prevent injury.
3.2.2

Specific aim 2: Utilize Poly(trolox) nanoparticles to treat the damage
caused by rheumatoid arthritis in vivo

A. Encapsulate poly(trolox) in a biocompatible polymer that provides stealth
properties and long circulation times in vivo.
B. Investigate the ability of poly(trolox) nanoparticles to accumulate in inflamed
joints and tissue.
C. Study the effects of antioxidant therapy on the deleterious effects in the joints of
rheumatoid arthritis
3.2.2.1

Hypothesis #2
The antioxidant protection provided by poly(trolox) nanoparticles can inhibit the
oxidative stress and inflammation stemming from rheumatoid arthritis

3.2.2.2

Significance and Outcome

In Chapter 5 we describe how we can utilize our antioxidant nanoparticles into an in
vivo injury that is clinically relevant. Rheumatoid arthritis is an autoimmune disease that
causes localized inflammation, oxidative stress, and damage to joints and cartilage. We
found that our particles can accumulate at the inflamed joints due, in part, to the EPR-like
effect from the disrupted vasculature. These particles did not appear to reduce the
symptoms of arthritis by a visual scoring system. However, upon further analysis it was
found that they did in fact reduce oxidative protein damage, recover antioxidant capacity,
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and significantly down regulate cytokine levels associated with oxidative stress, such as
IL-6 and TNF-α.

3.2.3

Specific Aim 3: Develop a novel anti-inflammatory polymer delivery system
to inhibit the incidence of cancer metastasis

A. Synthesize and characterize an anti-inflammatory poly(beta-amino ester) of
apigenin
B. Investigate the activity, loading potential, and release characteristics of apigenin
PβAE nanoparticles
C. Evaluate the potential of apigenin PβAE nanoparticles to prevent tumor cell
adhesion to inflamed vascular beds.
3.2.3.1

Hypothesis #3
Apigenin PβAE nanoparticle systems can be utilized to prevent inflammationmediated tumor cell adhesion to endothelial cells.

3.2.3.2

Significance and Outcome

A linear chain polymer comprised of apigenin was developed as described in Chapter
6. This polymer was formed into a nanoparticle delivery device similar to other chapters.
It was found that the PβAE loaded nanoparticles released active therapeutic for up to 72
hours. The apigenin PβAE was effective in reducing inflammation, as observed through
inflammatory CAM analysis. As a benefit of these anti-inflammatory properties, the
potential of circulating tumor cells to adhere to vascular cells was reduced.
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Chapter 4. Suppression of Iron Oxide Injury
Based on the research article:
David Cochran, P. Wattamwar, R. Wydra, J.Z. Hilt, K.W. Anderson, R. Eitel, and T.
Dziubla. “Suppressing Iron Oxide Nanoparticle Toxicity by Vascular Targeted
Antioxidant Polymer Nanoparticles”, Biomaterials.

4.1 Introduction
Owing to their superparamagnetic properties [166], iron oxide nanoparticles have
seen applications as varied as MRI contrast agents [167], iron supplementation in cases of
anemia [168], localized hyperthermia generation for increased drug efficacy, or even
direct thermoablation of tumor tissue [169]. Additionally, researchers have exploited the
controllable size, shape, and potential surface chemistry of these nanoparticles to develop
targeted therapy strategies utilizing the iron oxide core. For example, the core can be
modified with a poly(ethylene glycol)-based hydrogel shell that entraps a wide range of
therapeutics, or consist of surface-bound targeting ligands such as antibodies or peptides
[170, 171]. However, despite clinical acceptance, the use of iron oxide particles has also
come under scrutiny owning to their ability to induce cellular toxicity and nephrotoxicity.
Due to their size, ultrafine iron oxide nanoparticles, either in a biomedical setting or in an
environmental contaminant setting (e.g., miners, industrial manufacturing, etc.), are
readily internalized within cells, including the vascular endothelium [172, 173]. Toxicity
associated with iron oxide nanoparticles stems, in part, from catalytic generation of free
radicals through Fenton chemistry [174], leading to oxidative stress. Even iron oxide
particles stabilized with coatings such as dextran or citric acid have demonstrated
oxidative stress induction [175].
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Oxidative stress is a key pathological process in a variety of disease states (ischemia –
reperfusion injury [1, 2], acute lung [3] and renal injury [4]) and is characterized by the
formation of a wide range of reactive oxygen species (ROS), which can cause severe
DNA, protein, and lipid damage leading to cellular dysfunction and death [5, 6].
Theoretically, it should be possible to mitigate iron oxide induced cell injury by
delivering antioxidants directly to the site of injury [25-27]. Yet, in order to realize
antioxidant therapy for treatment of iron oxide toxicity, it must be possible to deliver
active antioxidant directly to the site of action for a sufficient time [28, 29]. In the case of
most biomedical applications of iron oxide nanoparticles (e.g., MRI [176] and
chemotherapy adjuncts [177]), this site of action is the vascular bed.
Orally administered antioxidants are mostly inactivated through first pass metabolism
well before they are able to reach the vascular bed [178]. Indeed, due to the highly labile
nature of antioxidants, even direct injection fails to accumulate in the vasculature cells at
sufficient levels to be effective. To overcome the stability limitation, we have previously
reported on a the development of a degradable antioxidant polymer, poly(trolox) (PTx),
which demonstrated the ability to suppress oxidative cellular stress [22]. This polymer is
readily synthesized into nanoparticles that can suppress the formation of oxidized cellular
products [22]. In this work, we extend this capability by actively targeting poly(trolox)
nanoparticles to vascular endothelial cells through surface coating of the nanoparticles
with platelet endothelial cellular adhesion molecule-1 (PECAM-1) antibodies.
PECAM-1 is a member of the immunoglobulin superfamily that regulates cell-cell
adhesion and transmigration [179-182]. It is an especially useful target for vascular
targeting due to its constant expression at cell-cell boarders in the endothelium [180].
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PECAM-1 provides an excellent basis for targeting antioxidants to vascular beds, one of
the primary residence areas for iron oxide nanoparticles. Previous work has demonstrated
the ability to physically absorb targeting antibodies to therapeutic particles for active
targeting to specific adhesion molecule groups [183-185]. These targeting antibodies
have shown to have higher specificity towards sites of interest, especially in tumors and
organs, as compared to non-targeted therapeutics [186, 187].
We hypothesize that by combining antioxidant polymer nanoparticles with the active
endothelial targeting provided by antibodies directed towards PECAM-1, an effective
therapeutic can be realized that has the capacity to intercept and prevent the free radical
damage caused by the accumulation of iron oxide nanoparticles in vasculature used in
many applications.

4.2 Materials and Methods
4.2.1

Reagents

All reagents received were used without further purification. Poly(trolox) 1000 and
2500 were synthesized in lab as previously reported [188].
2', 7’-dichlorodihydrofluorescein diacetate (DCF-DA) was purchased from
Invitrogen. DyLight 488 antibody labeling kit, anti-mouse IgG counterstain, and 4', 6diamidino-2-phenylindole (DAPI) nuclear stain, were purchased from Piercenet.
Nonspecific mouse IgG was purchased from JacksonImmuno. Mouse anti-human antiPECAM-1 antibodies were created and purified in house through the use of hybridoma
cell lines (cell line designation P2B1) purchased from the Developmental Studies
Hybridoma Bank. Na125I (Sodium Iodide) was purchased from Perkin Elmer. Polystyrene
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beads were purchased from Polysciences Inc. Gel-clot LAL endotoxin test kits were
purchased from Lonza. All other materials and solvents were purchased from SigmaAldrich.
4.2.2

Citric acid coated iron oxide nanoparticle formulation

A one-pot co-precipitation method was used to prepare the core citric acid coated iron
oxide nanoparticles as previously reported [189]. Briefly, an aqueous solutions of
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio in a sealed three-neck
flask under vigorous stirring and an inert N2 environment. Once 85 °C was reached,
NH4OH was injected into the vessel followed by 2 M citric acid. The reaction was carried
out for 1 hour. The particles were washed with ethanol and retrieved with magnetic
decanting. Following the wash, the particles were dried and stored under vacuum.

4.2.3

Poly(trolox) nanoparticle formulation and characterization

A single emulsion technique was used to formulate nanoparticles. Initially,
poly(trolox) was dissolved in acetone. This solution was then added drop wise into
methanol vortexing at 2000 RPM. The final concentration of acetone to methanol was
10% v/v. The nanoparticle solution was then dialyzed against sterile PBS overnight. The
dialyzed solution was then centrifuged three separate times at 22,000 RPM for 1 hour and
resuspended in fresh sterile DI water to remove all traces of methanol, as confirmed by
GC analysis (data not shown). Particle size and zeta potential was measured after
centrifugation using dynamic light scattering on Malvern Zetasizer Nano.
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4.2.4

Antibody loading and characterization

AntiPECAM-1 and mouse IgG were radiolabeled with 125I using the Iodogen Method
(Pierce Chemical) and purified using Bio-Rad Desalting columns, as previously
described.[182] Antibody concentrations totaling 10,000 AB/µm2 were incubated with 1
mg of PTx and Polystyrene nanoparticles (100 nm) overnight at 20ºC. Bovine Serum
Albumin (Fisher Scientific) in PBS was then added to a final concentration of 1% BSA to
block remaining surface sites for 1 hour before use. Particles were then washed in
triplicate by centrifuging at 22,000 RPM for 30 minutes and resuspended in 1% BSA to
wash away unbound antibody. Antibody was traced in both supernatant and pellets using
a PerkinElmer 2470 Automatic Gamma Counter. Stability was determined by storing
nanoparticles at 20ºC for one week, then repeating the centrifugation cycle.
4.2.5

Antibody and particle binding to HUVEC model

HUVECs were obtained by Lonza and cultured in EGM-2 media (Lonza)
supplemented with penicillin and streptomycin. HUVECs, passage 4 to 8, were seeded at
a density of 25,000 cells/cm2 and cultured overnight in 24 well plates. Antibody coated
particles were then incubated with cells for 30 minutes. Following incubation, HUVECs
were rinsed 5 times with PBS. Cells were lysed using a solution of 5% Triton-X 100 and
0.1 N sodium hydroxide in PBS and lysates were analyzed using a gamma counter.
Antibody molecules per cell were estimated by the masses recorded and area of the
microplate well divided by the average area of a cell, assuming complete confluence.
4.2.6

In Vitro iron oxide nanoparticle toxicity assessment

HUVECs were seeded at a density of 25,000 cells/cm2 were cultured for 24 hours.
Iron oxide nanoparticles in media were placed in a sonicating bath for 2 hours to aid in
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suspension. Iron oxide nanoparticles were then added to the cells. After 24 hours, cells
were washed 3 times using warm media. Viability was determined by incubation of
Calcein AM for 30 minutes and fluorescence measured at 495ex/515em. Viability was
measured by the following equation, where the control refers to untreated cells:
% 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 =
4.2.7

𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏

In Vitro cellular protection against background oxidative stress

HUVECs seeded at a density of 25,000 cells/cm2 were cultured for 24 hours. DCFDA at a concentration of 10 µM was added and one hour later, polymers nanoparticles
added. After 30 minutes, the cells are washed 5 times using warm media to remove
unbound particles. 24 hours later, fluorescence was measured from bottom at an
excitation wavelength of 485 nm and emission wavelength of 528 nm using a GENios
Pro fluorescence spectrophotometer. Percent protection from the antioxidant polymer was
by the following equation, whereas the control refers to untreated cells that underwent the
same washing steps:
% 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =
4.2.8

𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝐹𝐹𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏

In Vitro cellular protection against iron oxide induced oxidative stress

HUVECs were prepared as in the previous section. AntiPECAM-1/PTx-1000 at 0.5,
and 1 mg/mL, AntiPECAM-1/PS, and IgG/PTx 1000 at 1 mg/mL were incubated for 30
minutes. Afterwards, the cells are washed 5 times using warm media to remove unbound
particles. Additionally, PTx 1000 without any targeting coating was incubated for the
entire duration of the experiment. One hour later, iron oxide nanoparticles were added at
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a concentration of 30 µg/mL. After 24 hours, ROS levels were recorded as previously
described. Viability was determined by incubation of Calcein AM for 30 minutes and
fluorescence measured at 495ex/515em. In order to account for dead cells exhibiting no
DCF fluorescence, normalized percent protection from injury by the antioxidant polymer
was obtained by the following equation:
% 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =

% 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
% 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉

Additionally, to determine endotoxin levels, iron oxide nanoparticles were subjected
to gel-clot LAL endotoxin analysis according to manufacturer’s instructions.
4.2.9

Determination of particle internalization

HUVECs were seeded on glass slides and grown to confluence. Green fluorescent
polystyrene beads (200 nm) were coated and purified with anti-PECAM-1 and IgG as
described previously. Antibody coated particles were then added to HUVEC cultures and
washed 5 times using warm media after 30 minutes at 37ºC. Cells were than fixed in 2%
paraformaldehyde solution either immediately or after 8 hours. Following fixation, cells
were labeled with secondary antibody for 30 minutes and washed. Cells were
permeabilized and stained with DAPI. Glass slides were than imaged utilizing a
fluorescent microscope and analyzed for internalization and particle counts (Nikon
Elements 4.2). In short, overlaid images depicting orange (red + green) particles were
marked as surface bound, whereas green particles were marked as internalized. Similarly,
particle counts per cell were determined by pixel area of all particles divided by the pixel
area of a single particle as determined by the Nikon Elements software.
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4.3 Results
4.3.1

Poly(trolox) nanoparticle synthesis and characterization

To promote physioabsorption of antibodies onto PTx nanoparticles, a surfactant-free
nano-precipitation method was developed. It was found that at the concentrations tested
(0.5, 1, 10 mg/mL polymer in solvent phase), the nanoparticle size was independent of
the initial polymer concentration (Figure 4-1). Formulations of nanoparticles with solvent
concentration of over 10 mg/mL resulted in significant aggregation and inconsistent
particle sizes. Particles ranged in size from 150 to 160 nm, within the limit for CAM
mediated internalization [190]. Analysis of the zeta potential for both PTx 1000 and 2500
revealed charges between -21 to -32 mV (Figure 4-1). This moderate negative charge
promotes the ability for physioabsorption of antibodies to their surface, providing a basis
for further targeting modification.
4.3.2

Antibody coating and stability determination

The ability to physically absorb targeting antibodies to the surface of PTx
nanoparticles was evaluated through the use of 125I-IgG tracing. Antibodies were
radiolabeled as described in the methods section. To aid in complete coverage,
antibodies were incubated with the nanoparticles at a solution concentration equivalent to
10,000 antibodies/µm2 particle surface area, 1.2 times the theoretical monolayer coating
based on antibody size and particle area. The particles were then centrifuged to separate
solid particles from free antibody. Based upon radiotracing of antibody bound to PTx
1000 and 2500 nanoparticles, we observe 57.04 ± 5.7% (PTx 1000) and 56 ± 4.7% (PTx
2500) surface coverage of antibody, or 826 ± 67 (PTx 1000) and 812 ± 66 (PTx 2500)
antibodies / particle (Figure 4-1).
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While physiochemical adsorption is a convenient and easy mechanism of nanoparticle
surface modification, if the adsorption strength is too low, the antibody coating could
potentially be replaced by other proteins found in serum and thereby lose targeting
capacity. To test the stability of the antibody coating, the particles were incubated at 4ºC
in 1wt% BSA for 7 days of storage. Importantly, it was determined that 94 ± 1.5% (PTx
1000) to 99 ± 1.3% (PTx 2500) of the antibody remained attached to the nanoparticle
surface, suggesting stability in storage conditions (Figure 4-1). This is consistent with
prior work with antibody coating of polystyrene and poly(lactic glycolic) acid
nanoparticles [191].
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Figure 4-1. Characterization of poly(trolox) nanoparticles
A single step, surfactant free solvent extraction method was used to prepare poly(trolox)
nanoparticles. Particle size (A) and zeta potential (B) were measured after centrifugation
using dynamic light scattering (M ± SD, n=3). Poly(trolox)-1000 and Polystyrene
nanoparticles were antibody coated using physioabsorption, with extent of adsorption
determined using 125I Radiolabeled IgG. Theoretical loading was determined as a ratio
of the surface area of the particle divided by the surface area of the Fc base fragment of
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the antibody (C) (approximately 3 nm x 3 nm) (M ± SD, n=3). Stability of antibody
coating was determined by monitoring the extent of antibody coating remaining on the
particle after 1 week incubation. Particles were then centrifuged for 30 minutes and pellet
examined in gamma counter to determine viability of antibody coating. Near 100% of the
antibody coating is retained after one week (D) (M ± SD, n=3).
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4.3.3

Iron oxide nanoparticles exhibit toxicity and ROS generation in Human
Umbilical Vein Endothelial Cells (HUVEC)

Although iron oxide nanoparticles have been formulated with many types of coatings
to inhibit either toxic effects or improve stability, they still are able to induce oxidative
stress within cells. Specifically, citric acid coated nanoparticles were tested due to their
emerging prevalence in early clinical trial biomedical applications, owing to their
hydrophilic properties and stability in aqueous media [192, 193]. These nanoparticles can
be easily produced and coated in a one-step synthesis reaction from the reduction of iron
salt in citric acid buffer.
While these particles are generally referred to as chemically unreactive, they directly
react with viability stains, such as MTT and MTS, which rely upon reduction to measure
cell activity [194]. To avoid this artifact, cell viability was assessed using Calcein AM
(live) stain, which relies upon esterase activity as a means of determining intact cells. In
this work, we observed a concentration dependent toxicity and ROS generation over a
period of 24 hours. The LD50 of iron oxide was determined to be 35 µg/mL. This
toxicity was related to the ability of the particles to induce oxidative stress as measured
by a 2', 7’-dichlorodihydrofluorescein (DCF) fluorescence assay. At 15 µg/mL, the DCF
fluorescence was 307 ± 33% over control at 24 hours (Figure 4-2). At increasing
concentrations of iron oxide nanoparticles, DCF fluorescence decreases due to significant
cellular death and detachment of cells.
4.3.4

AntiPECAM-1 and AntiPECAM-1/PTx nanoparticles, but not IgG, bind
specifically to HUVECs

In order to evaluate the ability of antiPECAM-1/PTx to adhere to vasculature, a
HUVEC cell culture model was once again employed. Binding of free antiPECAM-1
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antibody and antiPECAM-1/PTx were tested against nonspecific mouse IgG. In
antiPECAM-1/PTx studies, to eliminate the possible artifact of detached antiPECAM-1
adhering to the cell surface, antiPECAM-1/PTx binding was evaluated using a nonspecific 5wt% 125I-IgG tracer.
Concentration dependent binding profiles of both free antibody and coated particles
were observed and compared to the non-specific binding observed from IgG controls.
The antiPECAM-1/PTx nanoparticles exhibit an order of magnitude higher specificity
and adhesion with 350 particles/cell compared to 40 particles/cell for IgG coated particles
at an initial incubation concentration of 0.8 mg/mL.
It is interesting to note that in each concentration of the targeted antioxidant
nanoparticles, we conclude that 1/10th of incubated particles adhered to the cell
monolayer following five wash cycles (Figure 4-3).
4.3.5

Antioxidant function of AntiPECAM-1/PTx nanoparticles in HUVECs

To verify if antiPECAM-1/PTx nanoparticles are capable of inhibiting cellular
oxidative stress, a DCF assay was used. For PTx 1000, a dose dependent decrease in ROS
levels was observed, reaching a maximum of 19% reduction at 0.6 mg/ml.
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Figure 4-2. Iron oxide toxicity and ROS in HUVECs
HUVECs were incubated with iron oxide nanoparticles in a range of concentrations for
24 hours to determine viability and ROS levels. From the viability (A), the LD50 was
determined to be 35 µg/mL. A close-up view of ROS levels near this concentration are
shown in (B). ROS levels peak at 300% over background at a sub-lethal concentration of
15 µg/mL followed by a decline in level as significant cellular death occurs.
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In the case of PTx 2500, the 0.8 mg/mL concentration had an 18% reduction of
background oxidation, with no therapeutic benefit at lower concentrations. It is
hypothesized that this is due to the smaller molecular weight chains degrading faster,
thereby exhibiting a slight antioxidant effect, compared to the slower degradation of the
higher molecular weight species that are likely to be overcome by natural redox signaling
inside of the cell. In each concentration, the IgG/PTx shows no suppression of ROS. ROS
level is measured as a percent of control, HUVECs that were not exposed to any
treatment (Figure 4-3).
This MW behavior and dose dependence correlates well with previously published
results [45]. Comparing the level of suppression in relation to mass bound (1/10th of
incubated 1 mg/mL dose as determined in Figure 4-3) corresponds to previously
published literature for ROS suppression. In the previous publication, 0.1 mg/mL, the
relative mass bound for 1 mg/mL incubation concentration, of PTx 1000 and PTx 2500
exhibited 30% and 20% reduction in ROS respectively [45].
4.3.6

Suppression of iron oxide nanoparticle induced ROS injury through the use
of AntiPECAM-1/PTx

To determine if targeted poly(trolox) nanoparticles can prevent iron oxide toxicity,
1.0 and 0.5 mg/mL of antiPECAM-1/PTx and IgG/PTx nanoparticles were
prophylactically administered to HUVECs for 1 hour and rinsed 5 times prior to iron
oxide nanoparticle exposure.
Iron oxide at a concentration of 35 µg/mL induced a normalized ROS response that
was 180 ± 11% over untreated cells with a viability of 52 ± 7.2%. As non-targeted
particles do not significantly bind to HUVECs, IgG/PTx treatments did not provide
protection against iron oxide nanoparticle injury. For antiPECAM-1/PTx we observe
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43.5% suppression in ROS levels at 1 mg/mL and 47.7% at 0.5 mg/mL (Figure 4-4).
Interestingly, we see a dose dependent increase in viability, with a recovery of 92 ±
10.1% at 1 mg/mL dosage, and 65 ± 8.0% recovery at 0.5 mg/mL (Figure 4-4).
4.3.7

Determination of iron oxide nanoparticle injury suppression mechanism

It is proposed that the mechanism of iron oxide toxicity is due to the generation of
free radicals due to Fenton reactions. In the presence of hydrogen peroxide, Fe2+ can
undergo oxidation and Fe3+ can undergo reduction. The byproducts of this are highly
reactive hydroxyl and peroxyl radicals. We theorize that the antioxidant potential of
AntiPECAM-1/PTx nanoparticles can intercept these radicals, thereby attenuating
damage caused by iron oxide nanoparticles.
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Figure 4-3. Antibody and particle binding to cellular model with suppression of
background ROS
Free antibody and poly(trolox) nanoparticles were incubated with HUVEC cells in
varying doses. Antibody (A) and particles (B) were incubated for 30 minutes, followed
by 5 washes in warm media. AntiPECAM-1 and antiPECAM-1/PTx possessed an order
of magnitude higher binding to cells as compared to the non-specific IgG controls.
Approximately 10% of particles incubated stay adhered after washing (M± SD, n=3).
Oxidative stress was measured using DCF as a fluorescent probe. DCF was added to
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HUVECs for one hour prior to administration of antioxidant nanoparticles. Particles were
incubated for 30 minutes followed by 5 washings in warm media. Nonspecific IgG coated
nanoparticles show no suppression of oxidative stress as compared to the control in each
formulation. PTx 1000 shows a dose dependent decrease in oxidation. PTx 2500 shows
an effect at 0.8 mg/ml, but no significant protection thereafter. This can be attributed to
the slow degradation of PTx 2500 due to its higher molecular weight (C) (M± SD, n=3).
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Figure 4-4. Suppression of iron oxide injury
HUVECs were incubated with DCF for one hour then removed. Afterwards, antioxidant
nanoparticles were incubated 1 hour before introduction of iron oxide nanoparticles at a
concentration of 30 µg/ml. (A) DCF Fluorescence was measured 24 hours after injury.
(B) After DCF measurement, Calcein AM at 5 µM was incubated for 20 minutes, and
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fluorescence subsequently measured. IgG/PTx shows no significant protection from
ROS, or exhibit an increase in viability. AntiPECAM-1/PTx particles show suppression
of ROS levels as compared to control, however it does not appear to be dose dependent.
Viability for AntiPECAM-1/PTx however shows a dose dependent increase in viability,
indicating mitigation of iron oxide toxicity. (M± SE, n=3, * = p<0.05).
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However, it was not certain if the observed results in Figure 4-4 were due to the
antioxidant activity or if it was due to physically blocking/occupying possible
internalization routes, which would likely reduce the uptake of iron oxide. To determine
if this is a concern, the study was repeated using the targeted, but non antioxidant
antiPECAM-1/Polystyrene (PS) beads. As a comparison group cells were also incubated
with PTx-1000 nanoparticles that were not rinsed.
After a 24 hour incubation period of iron oxide, the AntiPECAM-1/PS treatment
showed no significant reduction in either viability or ROS levels; however 1.0 mg/mL
PTx 1000 nanoparticles exhibited 87.6 ± 3.4% recovery in viability, and significant
reduction in ROS levels (Figure 5). This indicates the protection mechanism is a linked to
the antioxidant potential of the targeted treatment, rather than inhibition of internalization
routes utilizing an active targeting method.
4.3.8

AntiPECAM-1 coated fluorescent particles exhibit significant internalization
following incubation

To determine if antiPECAM-1 antibody coated particles possess the ability to
internalize into a cell, an expected prerequisite for function, a fluorescent microscopy
approach was utilized. HUVECs were incubated with antibody coated green fluorescent
polystyrene beads for 30 minutes then washed as described before. Targeted particles
were then both fixed and counterstained with a Texas Red labeled goat anti-mouse IgG
either immediately or after an 8 hour incubation period to allow for cellular endocytosis
to occur.
Membrane bound particles will fluoresce both green (polystyrene) and red (Texas
Red secondary antibody stain) that, when overlaid, appear yellow. Particles that have
been internalized will be inaccessible to the secondary stain due to cell membrane
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fixation. These internalized particles will remain green. AntiPECAM-1 coated particles
showed an expected increase of internalization over the 8 hour time period, from 20% to
over 80% internalized, indicating significant internalization and delivery of particles to
the endothelial cells (Figure 4-6).
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Figure 4-5. Determination of protection mechanism
HUVECs were incubated with DCF for one hour then removed. Afterwards, targeted
polystyrene particles were incubated for 30 minutes then washed 5 times to remove
unbound particles. Conversely, poly(trolox) particles incubated for the entirety of the
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experiment. One hour after incubation iron oxide nanoparticles at a concentration of 30
µg/ml were introduced. DCF Fluorescence was measured 24 hours after injury. Black bar
represents background ROS levels (A). After DCF measurement, Calcein AM at 5 µM
was incubated for 20 minutes, and fluorescence subsequently measured (B). Targeted
polystyrene particles show no therapeutic effect towards iron oxide injury regarding
viability or ROS measurements. Poly(trolox) incubated for the duration of the experiment
shows a significant viability recovery and reduction in ROS levels, indicating protection
is a result of antioxidant capability. (M± SE, n=3, * = p<0.05 from control).
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4.4 Discussion
As motivation to this study, we hypothesized that targeted antioxidant nanoparticles
could suppress cellular injury associated with iron oxide nanoparticle use. By injecting
these particles either prior to or in tandem with iron oxide administration, it should be
possible to block associated vascular damage. In our prior work, poly(trolox)
nanoparticles were shown to degrade in the presence of cellular esterases and release
active antioxidant, which is capable of suppressing cellular oxidation. We have also
shown that this polymer has a unique ability to inhibit the formation of cellular oxidation
products that is not seen in the native free antioxidant [45]. However, these studies
centered on non-targeted free particles that, due to expected clear mechanisms, would not
accumulate in the vasculature in vivo. To accommodate antibody coating onto the
particle surface, the formulation approach was changed to eliminate surfactant. The
surface charges of these particles are complimentary to surface absorption of various
proteins allowing the ability to tailor the targeting antibody to multiple applications.
Using simple physioadsorption methods, the antioxidant nanoparticles were coated
with greater than 500 antibodies/carrier, permitting sufficient multimer binding and
observed affinity in cell culture. Protein coating on nanoparticles can serve to stabilize
them from aggregation. To this end, antibody nanoparticles were suspended and stored in
1wt% BSA. Importantly, it is possible that this BSA could over time replace the antibody
from the surface of particles during storage. However, it was found that there was no
statistically significant decrease in antibody coating over one week storage in refrigerator
conditions. When added to an endothelial cell culture model, these PECAM-1/PTx
particles were then shown to significantly adhere to the surface of the cells. The method
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of adhesion was shown to be antibody-antigen based, as particles coated in nonspecific
IgG had no inherent capacity to adhere to the cell layer.
Based upon prior work of poly(trolox), with esterase dependent hydrolysis, it was
assumed that antioxidant function would require cellular internalization into lysozymes
[22]. While it has been shown that antiPECAM-1 antibodies are not internalized [195],
antiPECAM-1 conjugates can indeed be taken up through CAM mediated pathways and
is typically independent of the substrate particle [190]. It is observed here that the
polystyrene particles, over the course of 8 hours, are internalized, and trafficked towards
the nucleus in lysosomes. This compartmentalization can enhance the degradation of the
antioxidant particles, leading to the release of active therapeutic. Indeed, the targeted
antioxidant particles exhibit the ability to suppress background ROS generation with no
detrimental effect on cellular viability.
The antioxidant properties of this polymer may be highly beneficial in the biomedical
field, especially with the emerging use of transition metal based nanoparticles that can
cause free radical formation such as iron, zinc, cerium, and titanium [196] and the
overarching theme of safety in biocompatibility. The mantra of small size and high
surface, and subsequently reactive, area of metal nanoparticles has led to a paradigm of
monitoring oxidative injury as it pertains to cytotoxicity.
In medical applications of iron oxide nanoparticles, direct IV injections are the
traditional route of administration. As such, the vasculature epithelium becomes the first
point of contact for these particles, and thus a crucial area to study toxic and oxidative
interactions. Similarly for environmental exposure, the pulmonary endothelium becomes
the settling area for inhaled particles, which can cause significant inflammation and tissue
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damage. Not only is the endothelium the first point of contact in iron oxide exposure, it
has also been demonstrated that these cells are highly prone to oxidative damage and
injury [197]. Therefore, if protective particles are injected prior to iron oxide
administration, it should be possible to mitigate its observed toxicity.
To test this iron oxide-based toxicity, we studied the dose dependent ROS generation
and subsequent toxicity of iron oxide nanoparticles. While we observe a sharp decline in
the free radical generation with higher concentration of iron oxide, it is hypothesized this
is due to detachment and membrane disruption of the cell monolayer, causing the
fluorescent DCF probe to leak out of the cells, only to be removed following washing
steps involved in the procedure. Due to this phenomenon, subsequent analysis of free
radical generation is normalized against the viability, in order to observe the ROS level in
the remaining living population. It should be noted that this toxicity could also be caused
by endotoxin load of the formulation, as endotoxin has been shown to cause oxidative
stress related cellular activation [198]. While we do not have endotoxin calculations for
the exact particles used in this study, a similarly prepared batch that has been in storage
for 2 months was assayed. Endotoxin values were found to be below detectable levels, or
less than 0.015 endotoxin units (EU) per milligram of iron oxide nanoparticles. At this
level, endotoxin would be well below needed values to elicit a ROS response, reported to
occur as low as 150 EUs [199, 200]. Further, the toxicity and ROS generation exhibited
by iron oxide nanoparticles correlates with results found by other groups [201], and
provides a sound basis for evaluating the ability of antioxidant polymers to mitigate this
damage.
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Figure 4-6. Particle adherence and internalization
HUVECs were incubated with antibody coated green fluorescent polystyrene beads for
30 minutes. Following removal of unbound particles, cells were fixed either immediately
or after 8 hours of incubation. Cells were then labeled with red secondary for 30 minutes,
washed, then permeabilized and stained with DAPI nuclear stain. Imaging was done
utilizing a fluorescent microscope, and analyzed utilizing Nikon Elements. Particles that
appear yellow (red + green) are said to be bound to the outside of a cell. Particles that
appear green are said to be internalized. Particle counts per cell were also obtained
utilizing Nikon tracking software. 30 minutes after incubation, 20% internalization is
observed, after 8 hours this increases to over 80%. Particles adhered per cell for
antiPECAM-1 targeting were an order of magnitude higher than IgG coated (fluorescent
image not shown), similar to radiolabeling results in Figure 2. (M± SE, n=10).
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When the antiPECAM-1 PTx particles are added to cells before introduction of the
iron oxide nanoparticles, a significant recovery in both viability and ROS generation is
seen. Particles with a nonspecific IgG coating show no statistically significant effect on
viability. This is to be expected considering the adhesion data, where no accumulation of
nanoparticles is seen with the IgG coated particles. From this data, we concluded two
possibilities of protection, either that the adhered nanoparticles are physically blocking
the internalization pathway of the iron oxide or the antioxidant potential of the
nanoparticles is indeed protecting the cells (Figure 4-7). In order to elucidate the actual
protection mechanism, non-targeted PTx nanoparticles and targeted polystyrene particles
were employed. If the polystyrene particles, being the same size and having no intrinsic
therapeutic value, prevented cytotoxicity then it could be concluded that the protection
mechanism is due to the prevention of iron oxide from reaching the cell. However, we
observed that the polystyrene particles offer no protection, whereas the non-targeted
antioxidant particles once again recovered cellular viability, strongly indicating the
therapeutic efficacy of trolox.

67

Figure 4-7. Proposed protection mechanism of antiPECAM-1/PTx nanoparticles
A cartoon depicting the proposed protection mechanism provided by antiPECAM-1/PTx
nanoparticles. On the left: Bound antiPECAM-1/PTx nanoparticles (green) adhere to the
surface of the cell. These nanoparticles are then internalized, where cellular esterase
degrade the PTx nanoparticle into the active antioxidant trolox. On the right: Iron oxide
nanoparticles are internalized, where they undergo Fenton reactions. Endogenous
hydrogen peroxide reacts with Fe2+ and Fe3+ to form hydroxyl and peroxyl radicals,
which induce oxidative stress. Trolox can intercept these free radicals, mitigating the
damage caused.
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4.5 Conclusions
The antioxidant polymer poly(trolox) was successfully formulated into nanoparticles
coated with an antibody directed towards PECAM-1. These active targeting nanoparticles
have shown to adhere to HUVEC cells, internalize, and reduce oxidative stress in both
static and iron oxide mediated ROS injury type models. This targeted delivery system
shows great promise as a prophylactic or possibly tandem delivery system to vascular
beds, the common final destination of therapeutic iron oxide nanoparticles, in order to
mitigate the growing concern of toxicity.
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Chapter 5. Inhibition of inflammation-mediated rheumatoid arthritis
Based on the research article:
David Cochran, L. Gray, K.W. Anderson, and T. Dziubla. “Encapsulated Apigenin-based
Polymers for the Prevention of Tumor Cell Adhesion and Metastasis” (In review).

5.1 Introduction
In the previous chapter, we have demonstrated the link between oxidative stress and
injury through the use of iron oxide as a vascular injury agent. To further test the ability
of poly(trolox) to inhibit injury, we have utilized an in vivo injury consisting of
rheumatoid arthritis (RA). It is an autoimmune disease that primarily affects the joints of
the hands [202]. In RA, a host of immune cells such as T cells, B cells, and macrophages
infiltrate the pannus surrounding joints and begin to digest and injure articular cartilage
and bone [203]. It has been shown that reactive oxygen and nitrogen species are produced
at the site of synovitis [10]. This buildup can contribute further to the inflammation and
activation of immune complexes, resulting in increased damage to bone and tissue [15,
41]. In fact, researchers have reported that oxidative stress in RA leads to reduced
antioxidant capacity in tissues [42]. In regards to therapy options, other groups have
reported on the utilization of supplemental antioxidant therapy to inhibit injury with
mixed results [35, 204], with the prime cause of treatment failure pointed towards
ineffectual delivery and accumulation [205]. In separate studies, it’s been shown that
vitamin E can also inhibit inflammation via prostaglandin E2 down regulation [206].
Our polymer nanoparticle systems have the ability to overcome the issues of
premature oxidation and non-selective delivery. Indeed, it has been shown that nanoemulsions of vitamin E have increased bioavailability and accumulation in other in vivo
inflammation models [207]. With the unique oxidation suppression provided by
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poly(trolox) over trolox [45], it’s feasible that a controlled delivery system thereof,
capable of accumulating in inflamed joints, could potentially be used to inhibit or prevent
the progression of rheumatoid arthritis in vivo.
5.2 Materials and Methods
5.2.1

Polymer synthesis

mPEG-PLA: DL-lactide was initially recrystallized in anhydrous ether to remove
residual water and impurities. The purified DL-lactide was then stoichiometrically mixed
with mPEG and 1% stannous 2-ethyl-hexanoate in dichloromethane (DCM) to form a
polymer of a final molecular weight of 55,000. The resulting solution was heated to 90°C
under continuous nitrogen purge until all solvent was evaporated. Following this, the
ring-opening polymerization reaction proceeded for 6 hours at 120°C. The polymer was
then cooled overnight, dissolved in DCM, precipitated in cold diethyl ether, and freezedried then stored till further use.
5.2.2

Nanoparticle formulation and characterization

Formulation: mPEG-PLA and poly(trolox) were dissolved in acetone (10 and 5
mg/mL, respectively, 1 mL total). The mixture was added drop-wise to 20 mL of
deionized water mixing at 2000 RPM. Solvent was allowed to evaporate by stirring
overnight, and the solution was filtered through a 1 µm filter and centrifuged at 40,000g
for 15 minutes. This was followed by resuspension in sterile PBS with 1% BSA added.
Nanoparticle recovery was determined using a PEG-barium iodide complex assay.
Briefly, a known mass of nanoparticles were dissolved in 200 µL of 5 M NaOH for 4
hours at 80°C then neutralized with 5 M HCl. The solution was then mixed with a
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solution barium iodide, the absorbance was determined at 550 nm. This was then
compared against PEG standards, and compared to initial PEG content before
formulation.

Nanoparticle size: Particle size and polydispersity (PDI) were investigated using
dynamic light scattering (DLS). Nanoparticles were diluted in PBS at 25°C to a
concentration of 0.1 mg/mL then measured for size.

Drug loading: To determine total drug loading, nanoparticles were formulated as
described above with a slight exception. After the initial centrifugation, the supernatant
and nanoparticle mass were freeze-dried overnight, then dissolved in acetone. The
absorbance was then measured and compared against standards of poly(trolox) in acetone
at 370 nm. Encapsulation efficiency and drug loading was determined by the mass in the
supernatant compared to the mass in the nanoparticles:
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡) 𝑖𝑖𝑖𝑖 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
∗ 100%
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡) 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎

𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 =

5.2.3

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡)
∗ 100%
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚

Induction of arthritis in vivo and treatment regimen

Arthritis was induced in wild-type DBA/1 LacJ mice through the use of a Collagen
Antibody-Induced Arthritis model (CAIA) according to manufacturers supplied protocols
(Chondrex, Inc). In brief, mice were given an intraperitoneal injection of 2 mg of
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collagen antibody. Three days later this is followed by an intraperitoneal injection of 50
µg lipid polysaccharide (LPS). Animals were treated daily on day 3 on with mPEGPLA/PTx nanoparticles (125 µL at a 50 mg/kg concentration) or 1% BSA in PBS as
control for a total of 5 days via the tail-vein.
Extent of injury was assessed each day for a period of 7 days following initial
antibody injection by a visual-based scoring system provided by the manufacturer, along
with tracking of animal weight. Following the 7th day, the animals were sacrificed and
tissues collected for further analysis.
5.2.4

Assessment of nanoparticle accumulation in vivo

On day 7, the animals were injected with a slightly modified treatment. For mPEGPLA/PTx treatment, a near IR fluorescent dye Cy 5.5, obtained from Lumiprobe
(Hallandale Beach, FL), was incorporated into the nanoparticle formulation at a final
concentration of 2 wt%. Control group animals received an identical concentration of Cy
5.5 in saline.
After sacrifice, the whole animal and excised paws were imaged utilizing an IVIS
Spectrum imaging system (Caliper Life Sciences) at a wavelength of 673/707 ex/em.
Fluorescent intensity of the animal cavities and paws were recorded and exported for
analysis in ImageJ.
5.2.5

Determination of endogenous antioxidant activity in liver.

Following sacrifice, the whole animal liver was collected and homogenized in PBS. A
Myoglobin based colorized antioxidant equivalence content assay was utilized to
determine antioxidant activity. A mixture of myoglobin (Sigma) and potassium
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ferricyanide was added in PBS, and allowed to react in the dark for 5 minutes. The
oxidized myoglobin was separated from the potassium ferricyanide through the use of a
Sephadex spin column (Biorad) and diluted in PBS to a concentration of 6 µM. Next, 8
µL of liver homogenate, 100 µL of the 6 µM myoglobin solution, and 100 µL of 2, 2’azino-bis (3-ethylbenzothiazoline-5-sulphonic acid) (ABTS) at 0.8 mg/mL were added to
a 96 well plate and well mixed. The assay was started when 40 µL of 250 µM hydrogen
peroxide was added. After 6 minutes, the colorization of the ABTS was measured at 734
nm, and plotted against a generated calibration curve of trolox. Trolox equivalence was
then normalized to a known mass of tissue homogenate and compared.
5.2.6

Protein oxidation of paw tissue

To measure the effect of oxidative stress and injury in paw tissue, a 2, 4dinitrophenylhydrazine based protein carbonyl colorimetric assay was used according to
manufacturer protocols (Cayman Chemical). In brief, whole paws were homogenized in
MES buffer and solids centrifuged and removed. The protein containing solution was
then mixed with a solution of 2,4-Dinitrophenylhydrazine (DNPH) and hydrochloric acid.
After reaction on ice for 15 minutes, the protein was precipitated in a solution of
trichloroacetic acid and excess DNPH removed. Finally, the protein pellet is resuspended
in guanidine hydrochloride and absorbance measured at 370 nm using a plate reader.
Carbonyl content was measured per milligram of total protein content as measured by a
Bradford assay.
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5.3 Results
5.3.1

Nanoparticle formulation and characterization

To formulate a biocompatible delivery system for poly(trolox), a single-step
nanoprecipitation method was utilized. Table 6.1 outlines the size, encapsulation
efficiency, and final drug loading of each formulation. Blank mPEG-PLA nanoparticles
were determined to be 144.1 ± 13.5 nm with a polydispersity index (PDI) of 0.176 by
DLS. Nanoparticles with incorporated poly(trolox) were slightly larger at 163.1 ± 11.7
nm, a PDI of 0.313, with a final drug loading of 24.8 ± 2.08%.
5.3.2

Assessment of mPEG-PLA/PTx nanoparticles to suppress rheumatoid
arthritis

To evaluate if mPEG-PLA/PTx nanoparticles possess the capacity to inhibit oxidative
stress and inflammation in vivo, mice were subjected to a CAIA arthritis model. After a
booster shot of LPS on the third day after antibody injection, treatment began with daily
tail-vein injections of mPEG-PLA/PTx nanoparticles or saline. The animal paws were
evaluated each day utilizing a scoring system provided by the manufacturer, ranked
depending on severity of swelling. Figure 5-1 outlines the scoring trend and body weight
of the animals over time. Animals in the control group demonstrated a sharp rise in
incident score after 3 days of 4.3 ± 2.1, and continued to climb as expected, hitting a
plateau of 10.3 ± 1.3 at 6 days. Animals treated with mPEG-PLA/PTx nanoparticles
experienced a delay in arthritis symptoms, taking 5 days to reach a significant scoring
level of 3.0 ± 1.5. Symptoms plateaued after 6 days, similar to the control group, at a
scoring of 6.7 ± 2.0.
Analysis of body weight over time indicated a decline in weight following LPS booster at
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day 3, with a weight loss of 5%. Animals from both groups declined in an identical
fashion, a symptom of illness, to a maximum of 15% weight loss after a period of 7 days.
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Table 5-1 Properties of mPEG-PLA nanoparticles
Nanoparticles without any incorporated PTx are 144.1 nm in size with a relatively
monodispersity. Poly(trolox) loaded particles are slightly larger at 163 nm and less
monodisperse. Encapsulation efficiency was determined to be 51%, with a total drug
loading of 24.8% (N=3, M±SD).

Drug
loaded
Core
PTx

Size (nm)

PDI

144.1 ± 13.5
163.1 ± 11.7

0.176
0.313
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Encapsulation
efficiency (%)
N/A
51 ± 1.04

Drug
loading
(%)
N/A
24.8 ± 2.08

A 15.0

Arthritis score

12.0

9.0

6.0

3.0

Control
PTx nanoparticles

0.0
0.0

3.0

4.0
5.0
Time (days)

6.0

7.0

B
35.0

Body weight (g)

30.0
25.0
20.0

Control

15.0

PTx Nanoparticles

10.0
5.0
0.0
0.0

3.0

4.0
5.0
Time (days)

6.0

7.0

Figure 5-1: Analysis of arthritis score and animal weight over time
Arthritis score and weight were recorded over a 7 day period. (A) Animals treated with
PTx nanoparticles showed a lag time between treatment and generation of symptoms
compared to control group. Both groups plateaued in score after 6 days. Body weight,
however, declined at identical rates for both groups (B) (N=3, M±SD).

78

5.3.3

mPEG-PLA/PTx nanoparticles accumulate in organs and joints

In order to test if mPEG-PLA/PTx nanoparticles can accumulate at the site of
inflammation, an important prerequisite to effectual therapy, a modification to the
nanoparticle formulation was made for the final day of delivery. A fluorescent dye,
Cy5.5, was added to the synthesis step to allow for particle imaging in an IVIS Spectrum
imaging system. Control animals were given an identical mass of dye in saline.
Mice treated with mPEG-PLA/PTx nanoparticles showed significant accumulation of
particles in the liver and kidneys with over 40 fold increase compared to free dye (Figure
5-2a). As expected, the animals in the control group quickly cleared and excreted the free
dye. Most interestingly, analysis of the excised paws of mPEG-PLA/PTx treated animals
revealed a 267% increase over controls. This suggests a significant effect of
accumulation in the inflamed tissue (Figure 5-2b).
5.3.4

Endogenous antioxidant activity is recovered through the use of mPEGPLA/PTx nanoparticles

A myoglobin based TEAC assay was employed to determine if supplemental
antioxidant therapy can restore normal antioxidant function, and thus inhibit the oxidative
stress and inflammation due to rheumatoid arthritis. Liver tissue was selected for analysis
over paw tissue, due to the large relative differences in mass and overall sensitivity of the
assay. Figure 5-3 shows the antioxidant levels of the mice. The control group had an
antioxidant equivalence of 1.93 ± .019 mM trolox per mg of tissue. Animals treated with
mPEG-PLA/PTx recovered to 2.43 ± 0.03 mM trolox per mg of tissue. For reference,
baseline levels of antioxidant capacity in non-arthritic mice have been reported to be
between 2.5-3.5 mM trolox per mg of tissue.
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Figure 5-2: Fluorescent images of nanoparticle accumulation in vivo
mPEG-PLA/PTx nanoparticles were formulated with a fluorescent dye to track
accumulation in vivo. Control groups were given a dose matching of dye. Treated animals
had a 40 fold increase of accumulation in liver and kidneys (A). In excised paw tissue, a
267% increase of accumulation over free dye was observed (B).
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5.3.5

mPEG-PLA/PTx significantly inhibits protein carbonyl content in the paws
of arthritic mice.

Utilizing a DNPH based protein carbonyl content assay, we looked at the ability of
mPEG-PLA/PTx to inhibit protein oxidation, a major sign of oxidative stress. Whole
paws were excised and washed in DI water to remove excess blood or clots. Protein was
then extracted and tested. Figure 5-4 outlines the levels of protein carbonyl content. The
control group contained 5.37 ± 1.07 nmol carbonyl per mg of total protein. This level is
significantly higher than baseline levels of non-arthritic mice. The group treated with
mPEG-PLA/PTx was vastly reduced down to 0.25 ± .025 nmol carbonyl content per mg
of protein. This level is suppression is even lower than reported basal levels of 2.5-3.5
nmol per mg of protein.
5.3.6

Antioxidant nanoparticles reduce levels of inflammatory cytokines associated
with oxidative stress

Tissue recovered from animal paws were subjected to PCR and RNA analysis to
determine levels of cytokine expression. Four cytokines were analyzed; IL-6, Cox-2, IL8, and TNF-α. There were no differences in IL-6 or Cox-2 expression between controls
and treated animals. However, levels of IL-8 expression were reduced by 54%, and TNFα expression by 81%.
5.4 Discussion
In previous chapters, we have discussed the ability of the novel antioxidant polymer
Poly(trolox) to suppress oxidative stress mediated-injury. In this work we have further
expanded this polymer platform to elucidate the connection between oxidative stress and
inflammation in a relevant
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Figure 5-3: Ability of mPEG-PLA/PTx to recover antioxidant capacity
Untreated animals have a suppressed antioxidant capacity, due to inflammation and
oxidative stress stemming from RA. Animals treated with mPEG-PLA/PTx nanoparticles
experienced a recovery in antioxidant capacity, back up to basal levels. (N=3, M±SD)

nmol carbonyl content
per mg protein

7
6
5
4

Basal Levels

3
2
1
0
Control

Treated

Figure 5-4: Suppression of protein carbonyl content of paw tissue
Arthritic animals had significantly elevated levels of carbonyl content of 5.37 ± 1.07
nmol carbonyl. In contrast carbonyl content was eliminated in treated animals, a feature
observed in previous publications with PTx. (N=3, M±SD)
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disease model of rheumatoid arthritis. By encapsulating PTx into a degradable PEGylated
polymer, we have developed a biocompatible polymer that offers longer circulation times
compared to free PTx alone.
Similar to the delivery system in chapter 5, we have devised a nanoprecipitation
strategy to encapsulate PTx into an amphiphilic polymer of mPEG-PLA. The resulting
nanoparticles were 163 nm in size, with a drug loading of 25%. This is similar to the
results obtained for our apigenin PβAE polymers, which coincidently are similar in
molecular weight and hydrophobicity.
In order to test the particles in vivo, the CAIA arthritis model was used. From an
initial observation of Figure 5-1, it appears clear that animals treated with mPEGPLA/PTx nanoparticles had inhibited levels of arthritis. However, it is very important to
note that treatment did not occur until after scoring on day 3 of the LPS booster. In this
situation, the control group of animals were scored significantly higher than the treatment
group, despite the treatment group not receiving any nanoparticle dosages yet. Despite
this, the increase in scoring between day 4 and 7 appeared identical between both groups.
Similarly, the decrease in body weight between both groups were also identical,
indicative of the progression of the disease. From a visual scoring system, it appears that
our antioxidant nanoparticles offer no protective effects. Several suggestions in further
studies have been proposed, such as recording of pain thresholds, gait analysis, and
synovial fluid analysis to further elucidate the effect of treatment.
For the last day of treatment, the animals were given a formulation that incorporated a
fluorescent tag. After sacrifice, it was observed that the nanoparticles had significantly
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accumulated in the liver and kidneys as expected for nanoparticles of this size. Most
interestingly however, was that these nanoparticles also accumulated in the paw tissue of
the inflamed joints. It is hypothesized this is due to an EPR-like effect, where disrupted
vasculature, poor circulation, and retained fluid allow for these nanoparticles to deposit
and accumulate.
After it was determined the antioxidant particles provided no therapeutic effects by
visual examination, we had addressed the chemical effects. First, the antioxidant capacity
of liver homogenate was assessed. Liver tissue was selected due to the prevalence of
nanoparticle accumulation via imaging, the size of the organ, and sensitivity of the
antioxidant assay. It was found that the control group had a suppressed level of
antioxidant capacity, which is to be expected. The animals in the treatment group,
however, had recovered to a healthy basal level of capacity.
Next the level of protein oxidation, a symptom of oxidative stress and inflammation,
was evaluated. Tissue from the paw region was removed and protein extracted. The
levels of carbonyl content were significantly elevated in the control group of arthritic
animals, at nearly 2x the basal level. Animals treated with mPEG-PLA/PTx had almost
zero carbonyl content (Less than 0.5 nmol/mg protein, approaching the minimum
sensitivity limit of the assay). This result is reinforced from a previous publication where
it was demonstrated PTx had the ability to suppress protein carbonyl content, a feature
not observed in the monomeric form of trolox [45].
To elucidate the connection between inflammation and oxidative stress, a series of
cytokine markers were examined. Utilizing RNA expression, we observed the levels of
IL-6, Cox-2, IL-8, and TNF-α. It was found that the levels of IL-6 and Cox-2 were not
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different between treated and control groups. It has been reported in literature that these
two cytokines are highly dependent on inflammation signals as opposed to only oxidative
stress [208-210], which can explain why no difference was observed. IL-8 was reduced,
and TNF-α expression completely eliminated. In a similar fashion, it has been reported
that IL-8 is selectively up regulated from oxidative stress injury [211, 212], whereas
TNF-α is a ubiquitously expressed cytokine in response to a multitude of injuries.
5.5 Conclusions
A single-step nanoprecipitation method to encapsulate the antioxidant polymer
Poly(trolox) was developed. By encapsulating PTx in the polymer mPEG-PLA, we have
created a stealth biocompatible polymer that is long circulating and can be used to treat
injury and disease in vivo. These mPEG-PLA/PTx nanoparticles served to reduce
cytokine markers stemming from oxidative stress and replenish total antioxidant content
in the organs of mice in an arthritic mouse model. Fluorescent imaging analysis of the
organs indicates significant accumulation over a 5 day period as compared to control
mice. Most importantly, imaging analysis suggests higher accumulation of nanoparticles
in the inflamed joints possibly due in part to enhanced permeation and disruption of
vasculature in the limbs.
These nanoparticles also served to significantly reduce the levels of oxidized protein
in the limbs, a marker of downstream damage due to inflammation. This preliminary data
serves as a potential therapeutic delivery system for the treatment of rheumatoid arthritis
and the accompanying inflammation-mediated damage caused.
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Chapter 6. Interrupting the Metastatic Cascade: Apigenin-based Polymer
Nanoparticles Inhibit Cancer Cell Adhesion
Based on the research article:
David Cochran, L. Gray, K.W. Anderson, and T. Dziubla. “Encapsulated Apigenin-based
Polymers for the Prevention of Tumor Cell Adhesion and Metastasis” (in review).

6.1 Introduction
Relationships between cancer pathology and inflammation have been observed for
nearly a full century [213]. Researchers have linked the rates of cancer progression with
inflammation in order to understand the connection between the two. One study reported
cancer rates of individuals suffering from bronchitis are as high as 24% [214]. Another
reported asbestosis cancer rates of 15% [215]. Even individuals undergoing chronic UV
exposure (eg. Sunburns, tanning, etc.) have cancer rates of up to 11% [216].
In addition, metastasis has been shown to occur in approximately 20-40% of patients
diagnosed with breast and testicular cancer, leaving patients with a typical median
survival time of 18-24 months [217, 218]. A recent study revealed that in 2009 an
estimated 58,000 women developed metastatic tumors as a direct result of breast cancer
[219]. The average healthcare cost was placed at $128,556 per patient, for a total cost of
over $7.4 billion per year [219]. Current treatments for metastatic tumors include
systemic therapy (i.e. chemotherapy or hormonal therapy) or local therapy (i.e. surgery or
radiation) [220]; however, there are currently no FDA-approved treatments for the
prevention of metastasis in metastatic-prone patients. In fact, the latest drug application
of Xgeva for inhibition of metastasis was rejected by the FDA [221].
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Stresses such as the mechanical forces involved during surgery have been shown to
initiate a cascade of signaling events which includes the production of pro-inflammatory
cytokines TNF-α [222], interleukins [223], and chemokines [224] that lead to localized
inflammation and the surface expression of Cellular Adhesion Molecules (CAMs).[225]
Subsequently, circulating tumor cells such as breast cancer and lymphomas have been
shown to utilize inflammatory CAMs (e.g. ICAM, VCAM, ELAM) for extravasation,
which then can lead to metastasis of these cancers [226, 227].
While the connection between metastasis and inflammation is well-known, NSAIDs
are usually avoided postoperatively due to the potential for increased risk of
hemorrhaging and immunosuppressive effects [228, 229]. Studies from the Baylor
College of Medicine have reported that nearly 5% of patients experience post-operative
hemorrhaging, and an overall increase of general surgical complications by 2.4x [230].
Furthermore, glucocorticoids (GCs) such as dexamethasone are contraindicated in
patients with osteoporosis, a common side effect of chemotherapy treatment [231].
Additionally, systemic administrations of GCs have a relevant immunosuppressant action
which has been hypothesized to increase the metastatic potential of shed tumor cells
[232].
This mechanism of immunosuppression is believed to be due to GC binding to
specific intracellular GC receptors (GR) in both vascular and immune system cells [233].
This complex then binds to multiple transcription factors and DNA motifs such as
activator protein 1 (AP-1) and inhibits NF-κB activation by induction of the protein Iκβ
[234]. Additionally, recent studies point to GC-induced modulation of other pathways
such as Lck and Fyn, along with protein kinase B and C [233]. This wide range of
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pathway modulation not only affects CAM expression, but also inhibits cytokine,
prostaglandin, and nitric oxide production [235, 236] which confers a significant
immunosuppressive reaction [237].
Flavones, notably the potent compound apigenin, have been reported to suppress
JNK, ERK, and AP-1 pathways by inhibiting phosphorylation of kinases [44, 238] or
pathway inhibitor proteins such as IκBα and IKK [239, 240], although the mechanism is
not fully elucidated. This inhibition of phosphorylation effectively arrests pathway
activation and stimulation, leading to the down regulation of ICAM-1, VCAM-1, and ESelectin, along with NF-κB, [36, 37] making them potential candidates as therapeutic
compounds for the prevention of cancer metastasis. Additionally, in vivo studies indicate
little to no systemic toxicity, nor compromising of immune system function in large
dosages as seen in GC and NSAID therapies, [241] potentially indicating safe usage after
surgery. It is believed this is the result of a more specific pathway of modulation [242], as
opposed to the “shotgun” levels of suppression from GC’s. Previous research groups
have published on the ability of apigenin to suppress monocyte adhesion [36] and tumor
cell adhesion [243] in endothelial cells. As a result, apigenin has been selected as the
molecule of interest to formulate into a promising drug delivery system.
The largest obstacle in flavonoid delivery is that in their natural form they exhibit poor
solubility and limited bioavailability [244]. Widespread studies of oral consumption of
both flavonoid-rich food and concentrated extract indicate little to no active form survives
the GI tract [245]. A study in flavonoid absorption involving healthy ileostomy patients
indicated less than 17% of a 100 mg oral dosage of pure flavonoid compound was
recovered even before GI tract entry. Furthermore, analysis of blood plasma peaked at 90
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ng/mL after 4 hour, or less than 0.38% of the initial dose [246]. In order to overcome this
drawback, we have developed a class of degradable polymer systems based on beta amino
ester (PβAE) chemistry. This chemistry allows for incorporation of flavonoids into the
backbone of the polymer, creating a tunable release system while additionally protecting
the active groups on flavonoids from premature oxidation.[188] As the polymer degrades,
the active form of apigenin is recovered. Additionally, by developing a nanoparticle
encapsulation delivery method, based on the biodegradable diblock copolymers
methyoxypoly(ethylene glycol)-poly(lactide) (mPEG-PLA), both apigenin and apigenin
PβAE polymers demonstrate slower release and high activity of active apigenin that can
potentially overcome the limits presented by poor solubility and stability, and potentially
provide a long-term delivery system. The benefits of incorporating a nanoparticle delivery
system in tandem with slow releasing polymer include; enhanced solubility and
bioavailability [247, 248], a delivery platform that can facilitate co-delivery of other
therapeutics, or modification of the nanoparticle surface to include targeting ligands such
as peptides or antibodies [249].

We hypothesize and report on that a novel delivery system containing a polymeric form
of apigenin can overcome the problems of poor solubility and stability while still retaining
the potential to prevent tumor cell metastasis.
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6.2 Materials and Methods
6.2.1

Polymer synthesis

mPEG-PLA: DL-lactide was initially recrystallized in anhydrous ether to remove
residual water and impurities. The purified DL-lactide was then stoichiometrically mixed
with mPEG and 1% stannous 2-ethyl-hexanoate in dichloromethane (DCM) to form a
polymer of a final molecular weight of 55,000. The resulting solution was heated to 90°C
under continuous nitrogen purge until all solvent was evaporated. Following this, the
ring-opening polymerization reaction proceeded for 6 hours at 120°C. The polymer was
then cooled overnight, dissolved in DCM, precipitated in cold diethyl ether, and freezedried then stored till further use.

Apigenin multiacrylate: One gram of apigenin was dissolved in 100 mL of dimethyl
sulfoxide (DMSO). To this solution, triethylamine was added at a molar ratio of 3:1 and
mixed at 500 RPM. Next acryloyl chloride was added drop-wise with the solution placed
in an ice bath at a molar ratio of 3.5:1. The reaction mixture was left stirring at room
temperature for 12 hours. Precipitated triethylamine hydrochloride salt was removed by
vacuum filtration in a separation flask. Distilled water at 20-fold excess was added to the
reaction solution to precipitate the apigenin multiacrylate and it was subsequently
refiltered. The powered apigenin was once again dissolved in DMSO and precipitated
using 0.1 M K2CO3 to remove any potential unreacted acryloyl chloride. After the final
wash step, the power was freeze-dried and stored at -20°C. Conversion of phenolic –OH
groups was determined utilizing 1H-NMR, HPLC, and FT-IR.
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Apigenin poly (β-amino ester) (PβAE): Two forms of apigenin PβAE were
formulated: a highly cross-linked film and a dispersible oligomeric form. To formulate
the PβAE film, a single-step addition polymerization of 50:50 wt% poly(ethylene glycol
400 diacrylate) (PEG400DA) and apigenin multiacrylate with the primary diamine
4,7,10-Trioxatridecane-1,13-diamine (TTD) was completed as previously published[188].
To formulate the oligomeric form, PEG400DA was first mixed with the secondary
diamine N, N’-Dimethyl-1, 3-propanediamine (NNDA) at a total molar acrylate to amine
ratio of 0.9:1 and allowed to react for 4 hours at 60°C. Following incubation, apigenin
multiacrylate in DCM (100% by weight of apigenin multiacrylate) was added to make a
final ratio of 80:20 wt% apigenin multiacrylate: PEG400DA and reacted for a further 12
hours at 60°C. Polymerization was monitored through FT-IR, and molecular weight via
GPC.
6.2.2

Degradation of apigenin PβAE films

To determine the activity of the pure PβAE polymer, films were placed in PBS (pH
7.4) at 37°C for 48 hours. The resulting solution was then freeze-dried, weighed, and then
dissolved in DMSO at known concentrations and stored at -20°C until further use in cell
culture assays.

6.2.3

Nanoparticle formulation and characterization

Formulation: mPEG-PLA and apigenin/apigenin PβAE polymers were dissolved in
acetone with 5% DMSO (10 and 5 mg/mL, respectively, 1 mL total). The mixture was
added drop-wise to 20 mL of deionized water with mixing at 1000 RPM. Solvent was
allowed to evaporate and the solution was filtered through a 1 µm filter and centrifuged at
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40,000g for 15 minutes followed by resuspension in an appropriate buffer; either PBS or
complete cell culture media. Nanoparticle recovery was determined using a PEG-barium
iodide complex assay. Briefly, a known mass of nanoparticles were dissolved in 200 µL
of 5 M NaOH for 4 hours at 80°C then neutralized with 5 M HCl. The solution was then
mixed with barium iodide, the absorbance was determined at 550 nm, and this was then
compared against PEG standards.

Nanoparticle size: Particle size and polydispersity (PDI) was investigated using
dynamic light scattering (DLS). After initial centrifugation, the nanoparticles were
resuspended in PBS at 25°C at a concentration of 0.1 mg/mL then measured for size.

Drug loading: To determine apigenin drug loading, nanoparticles were formulated
above with a slight exception. After the initial centrifugation, the supernatant and
nanoparticle mass were freeze-dried overnight, then dispersed in DMSO. The absorbance
was then measured and compared against standards of pure apigenin at 270 nm.
Encapsulation efficiency and drug loading was determined by the mass of drug in the
nanoparticles compared to the total mass added:
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 =

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑖𝑖𝑖𝑖 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
∗ 100%
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑖𝑖𝑖𝑖 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
∗ 100%
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
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6.2.4

In vitro drug release

To determine the rate of release of apigenin and apigenin PβAE from the mPEG-PLA
nanoparticles, the following approach was utilized. The nanoparticles were suspended in
1 mL of PBS (pH 7.4) at 37°C at a concentration of 0.1 mg/mL and placed in a shaking
water bath. At pre-determined time intervals, the nanoparticles were centrifuged at
40,000g for 15 minutes, and the supernatant absorbance was measured at 270 nm. The
buffer solution was then replaced with fresh buffer to maintain sink conditions.

6.2.5

Cell culture

All cell lines were cultured at 37°C with 5% CO2 and 95% humidity. Single donor
human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (St.
Hopkinton, MA) and cultured in EGM-2 media (Lonza) supplemented with penicillin and
streptomycin. HUVECs (passage 4 to 8) were seeded at a density of 50,000 cells/cm2 and
cultured overnight in 12 or 24 well plates. Human breast adenocarcinoma cells, MDAMB-231, were obtained from ATCC (Manassas, VA) and cultured with Leibovitz’s L-15
medium (ATCC) supplemented with 10% fetal bovine serum (FBS), penicillin, and
streptomycin. MDA-MB-231’s were seeded at a concentration of 25,000 cells/cm2 for all
adhesion studies. CellTracker Orange and Calcein AM were from Invitrogen Life
Technologies (Grand Island, NY). TNF-α was obtained from Promega (Madison WI).
Mouse anti-human VCAM-1 and DyLight 594 goat anti-mouse IgG antibody were
obtained from Millipore (Billerica, MA).
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6.2.6

Cell viability

HUVECs were seeded as described above and grown to confluence. The cells were
treated with either free apigenin, degraded apigenin PβAE (both in a final concentration
of 1% DMSO, along with appropriate controls), or directly with nanoparticles for 24
hours. Following this incubation period, the monolayers were washed once with media
then viability was determined through the use of Calcein AM according to manufacturer
protocols in a spectrophotometric plate reader. All treatment groups were compared to
non-treated control cells.
6.2.7

Determination of tumor cell adhesion in cell culture

HUVECs were initially seeded in well plates as described above and grown to
confluence. Cells were treated with the desired drug platform (free apigenin or apigenin
PβAE with 1% DMSO) at various concentrations for 20 hours. After incubation, TNF-α
at 10 ng/mL was added to induce inflammation for 4 hours. Following all treatments,
HUVECs were stained using Calcein AM according to manufacturer protocols. In
parallel, MDA-MB-231’s were trypsinized and stained with CellTracker Orange
according to the manufacturer’s protocol. After staining, the MDA-MB-231’s were
centrifuged and washed to remove excess dye, then diluted to working concentrations of
25,000 cells/mL in HUVEC media. The media from the HUVECs was subsequently
removed and replaced with MDA-MB-231-laden media and allowed to sit for 30 minutes
to allow for adhesion to the cellular monolayer. After removing the media, HUVEC
monolayers were then washed 3 times with fresh media to remove unbound tumor cells
and the fluorescence of the bound MDA-MB-231 and HUVEC cells was measured
(Calcein AM Ex/Em: 490 nm/ 520 nm, CellTracker Orange Ex/Em: 541 nm / 565 nm)
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utilizing the fluorescent plate reader. Sample images were also obtained utilizing a
fluorescent microscope. Tumor cell adhesion was determined against non-inflamed
controls as a function of tumor cell fluorescence (TCf) by HUVEC fluorescence (Hf):

𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑎𝑎𝑎𝑎ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

6.2.8

𝑇𝑇𝑇𝑇𝑇𝑇 − 𝑇𝑇𝑇𝑇𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
∗ 100
𝐻𝐻𝐻𝐻 − 𝐻𝐻𝐻𝐻𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

Time-dependent apigenin PβAE release in cell culture

Apigenin PβAE nanoparticles were suspended into HUVEC media at a concentration
of 1 mg/mL. This solution was then incubated in a sealed sterile container in an incubator
at 37°C for 24, 48, or 72 hours. The nanoparticles were centrifuged and the apigenincontaining media was utilized for the previously described tumor cell adhesion assay.
Non-loaded nanoparticles and pure media were also subjected to these time course
incubations as controls.
6.2.9

Quantification of inflammation suppression

HUVECs were seeded in well plates and grown to confluence. The cells were treated
with free apigenin or nanoparticle formulations (unloaded, apigenin loaded, apigenin
PβAE loaded) for 20 hours. Following this, the cells were washed once with media and
TNF-α at a concentration of 10 ng/mL was added for 4 hours. Cells were fixed using cold
2% paraformaldehyde in DPBS for 10 minutes. The primary antiICAM-1 antibody was
then added and allowed to sit for 45 minutes. After thorough washing with DPBS, the
secondary fluorescent antibody was added for 45 minutes and washed once more. CAM
expression was measured via fluorescence in a spectrophotometer.
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6.3 Results
6.3.1

Characterization of apigenin multiacrylate

Figure 6-1 outlines the reaction sequence of apigenin to apigenin multiacrylate. NMR
analysis reveals the disappearance of phenolic –OH peaks at 4.2 ppm (Figure 1) in the
acrylated form of apigenin, indicating successful conversion. The FT-IR spectra of both
apigenin and apigenin multiacrylate reveal the formation of a characteristic ester peak at
1740 cm-1, resulting from –C=O bonds (Figure 2). Analysis of multiacrylate injection in
HPLC indicated over 80% conversion to the acrylate form (data not shown).
6.3.2

Apigenin PβAE polymerization and characterization

Using a single step Michael addition polymerization scheme resulted in a dispersible
oligimeric form of apigenin (Figure 6-2). FT-IR analysis indicates the disappearance of
the acrylate C=C bond at 1620 and 1670 cm-1, with preservation of the ester peak at 1740
cm-1 (Figure 6-5). GPC confirms an average molecular weight of 2110 with
approximately 5.4 mers per polymer unit.
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Figure 6-1: Reaction schematic of apigenin to apigenin multiacrylate
Apigenin reacts with acryoyl chloride in the presence of triethylamine to form apigenin
multiacrylate.

O
O

O

O

O

A

A
O

A

O
O

NH

O
A

R N
H

NH
HN R

O
HN
R
HN

O

Apigenin multiacrylate

O

+
NH2

R

O
A

O

H 2N

N,N'-Dimethyl-1,3-propanediamine

Apigenin poly (beta-amino ester)

Figure 6-2: Reaction schematic for creation of apigenin PβAE
Apigenin reacts with NNDA to form a low molecular weight branched chain polymer.
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Apigenin

Apigenin
Multiacrylate

Figure 6-3: 1H-NMR analysis of apigenin and apigenin multiacrylate
Structure of apigenin and apigenin multiacrylate. Apigenin was reacted with acryloyl
chloride and purified. NMR scan reveal the disappearance of the phenolic –OH groups at
4.3 ppm, signifying successful conversion to acrylate groups.
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Figure 6-4: FT-IR analysis of apigenin and apigenin multiacrylate
Presence of the peak (dotted line) at ~1740 cm-1 of apigenin multiacrylate is a
characteristic signal of ester groups, signifying successful conversion of apigenin to
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Figure 6-5: FT-IR analysis of apigenin multiacrylate and the polymer apigenin
PβAE
The C=C peak at 1670 and 1620 cm-1, characteristic of acrylate groups, disappear
indicating reaction with the diamine NNDA. The ester peak at 1720 cm-1 remains in the
final PβAE polymer, indicative of successful polymerization.
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6.3.3

Characterization of nanoparticle formulations and release profiles

To formulate a delivery system for the highly hydrophobic apigenin and apigenin
PβAE, a single-step nanoprecipitation method was utilized. Table 5.1 outlines the size,
encapsulation efficiency, and final drug loading of each formulation. Blank mPEG-PLA
nanoparticles were the smallest at 144.1 ± 13.5 nm. Pure apigenin-loaded particles were
211.8 ± 20.8 nm with a final drug loading of 25 ± 1.8%. Apigenin PβAE-loaded particles
were larger at 256.0 ± 9.3 nm, with a slightly reduced loading at 19.2 ± 2.0%.
Outlined in Figure 6-6 are the release profiles of apigenin and apigenin PβAE from
the mPEG-PLA nanoparticles. Apigenin-loaded nanoparticles exhibit a large and
significant burst release within 4 hours of 54 ± 0.3%, a common occurrence for
polymeric nanoparticles [250]. The apigenin-PβAE loaded nanoparticles however
showed a marked suppression of this release, with only 35 ± 0.9% release within the first
4 hours.
Pure apigenin-loaded nanoparticles nearly release their full payload (over 80%) after
24 hours, whereas apigenin PβAE-loaded nanoparticles have released only 41% of their
payload, and continue to steadily release for up to 120 hours.
6.3.4

Evaluation of apigenin and apigenin PβAE toxicity and tumor suppression
capability

To evaluate whether apigenin or the degradation products of apigenin PβAE could
protect inflamed endothelium from tumor cell adhesion, a well plate-based tumor
adhesion model was developed. First, to find acceptable working concentrations of
apigenin, the toxicity of apigenin was determined (Figure 6-6a). Extrapolating from the
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viability data, a 4 Parameter Logistic (4PL) regression model was fitted. From the model,
the 50% inhibitory concentration (IC50) was 88 µM, in range of toxicity defined in
literature [251]. The onset of toxicity began at 50 µM. The degradation products of a
50:50 PEG:apigenin PβAE had an onset of toxicity at an equivalent apigenin
concentration of 27 µM, with an IC50 of 60 µM (Figure 6-6). The results indicate that the
medication and degradation products associated with the apigenin PβAE do not result in
potentially toxic byproducts.
Following this, HUVECs were incubated with 5, 10, and 20 µM of apigenin and the
equivalent apigenin concentration of 10 and 20 µM from the PβAE degradation products,
followed by treatment with TNF-α for 4 hours. It was observed that cells treated with
TNF-α had over 82% more adhered tumor cells compared to cells without TNF-α
treatment. This finding has been previously published by our group [252]. With each
concentration of pure apigenin treatment, the tumor cell adhesion percentage reduced to
background levels, with no statistical (P > 0.05) concentration dependence observed
(Figure 6-7a). The degradation products of apigenin PβAE did exhibit a concentrationdependent suppression effect, with 10 µM at 129 ± 7.0 % and 20 µM at 106 ± 5.1 %
adhesion over uninflamed controls (Figure 6-7b).
Additionally, cells treated with apigenin, but without TNF-α, showed no statistical
effect (P > 0.05) on tumor cell adhesion possibly indicative of the anti-inflammatory
mediated function of adhesion suppression. Due to this result, all further treatment
experiments were done in the presence of TNF-α.
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Table 6-1: Nanoparticle characterization summary.
Pure apigenin-loaded particles show higher entrapment efficiency (EE), lower size, and
drug loading (DL) efficiencies as compared to apigenin PβAE, possibly due to size
differences between the monomer and polymer forms (N=3, M±SD).
Drug-loaded
Core
Unloaded
Apigenin
Apigenin PβAE

Size
(nm)
144.1 ± 13.5
211.8 ± 20.8
256.0 ± 9.3

PDI

EE
(%)
N/A
49.0 ± 3.7
38.4 ± 4.1

0.176
0.412
0.299

DL
(%)
N/A
25.0 ± 1.8
19.2 ± 2.0

1.0
0.9
0.8
Mt / Minf

0.7
0.6
0.5

Apigenin

0.4

Apigenin PβAE

0.3
0.2
0.1
0.0
0

50

100

150

Time (hours)

Figure 6-6: Nanoparticle in-vitro release profile
Apigenin-loaded nanoparticles have a high burst effect, followed by near complete
release after 24 hours. Apigenin PβAE-loaded nanoparticles by contrast exhibit a smaller
burst release followed by a linear release profile up to 120 hours (N=3, M±SD).
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Figure 6-7: Apigenin and apigenin PβAE degradation product toxicity
(A) After 24 hours, the IC50 of apigenin is 88 µM, similar to previously published
literature. (B) The degradation products of apigenin PβAE demonstrate an IC50 of 60 µM
(N=3, M±SE).
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6.3.5

Apigenin and apigenin PβAE nanoparticles retain tumor cell adhesion
suppression capacity

Drug-loaded nanoparticles ranging from 0.3 mg/mL to 5 mg/mL were suspended in
HUVEC media and directly added to HUVECs without the addition of solubilization
agents. A 4PL regression model was fitted to the toxicity plots. Apigenin and apigenin
PβAE-loaded nanoparticles were determined to have IC50 values of 4.4 and 3.08 mg/mL,
respectively. Blank nanoparticles showed no toxicity over 5 mg/mL (Figure 6-9a).By
transforming the data to examine apigenin content only, the IC50 for apigenin is 855 µM
compared to 395 µM for apigenin PβAE (Figure 6-9b). Apigenin-loaded nanoparticles
retain their anti-inflammatory effect and suppress tumor cell adhesion, as observed in its
free form. At a nanoparticle concentration of 0.25 mg/mL a maximum suppression is
seen at 118 ± 9.4% adhesion over unstimulated controls (Figure 6-10). At 0.5 and 1
mg/mL an unexpected increase of adhesion is observed. Correlating the dosage to the
toxicity plot, we observe the onset of toxicity coinciding at 0.5 mg/mL. Apigenin PβAE
nanoparticles show a similar trend with a maximum suppression at 0.5 mg/mL (117 ±
14.1%). The higher dosage required is due to the combination of lower loading (19.2%
versus 25%) along with the polymer composition (80% apigenin multiacrylate:20% PEG)
Blank nanoparticles show no statistical effect (P > 0.05) on tumor cell adhesion, again
confirming the therapeutic activity to come from the apigenin payload.
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Figure 6-8: Apigenin and Apigenin PβAE tumor cell suppression activity: (A) Pure
apigenin suppressed tumor cell adhesion to non-stimulated control levels. Apigenin also
does not elicit further suppression response in HUVECs not treated with TNF-α. (B)
Apigenin PβAE products still retain suppression activity after degradation. (C)
Fluorescent micrographs of tumor cell adhesion. (Top) Calcein AM stained unstimulated
HUVECs with cell tracker orange MDA-MB-231 tumor cells. (Middle) TNF-α treated
cells show a marked increase in tumor cell adhesion. (Bottom) Apigenin treated cells
reduce adhesion levels to background. (*p < 0.05, N=3, M±SE).
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Figure 6-9: Apigenin and apigenin PβAE nanoparticle toxicity profile
(A) Blank nanoparticles show no toxicity up to 5 mg/mL whereas apigenin and apigenin
PβAE nanoparticles have IC50 values of 4.4 mg/mL and 3.08 mg/mL respectively. (B)
Both apigenin and apigenin PβAE-loaded nanoparticles have an order of magnitude
higher toxicity than their free form counterparts (855 µM and 395 µM respectively)
(N=3, M±SE).
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6.3.6

Extended release of apigenin PβAE nanoparticles provides potential long
term tumor cell adhesion suppression

Apigenin PβAE-loaded nanoparticles demonstrated continual release over a 120 hour
period. To test the hypothesis that these nanoparticles would release the active compound
over this time frame they were incubated in media at 37°C for up to 72 hours. The
supernatant, containing released apigenin was then utilized directly. The apigenin PβAEloaded particles continued to show increasing levels of activity over time. At 72 hours,
tumor cell adhesion decreased from 181 ± 6% to 123 ± 12% (Figure 6-11a).
Extrapolating from the release curves, at 72 hours, approximately 67% of the drug
payload was released, correlating with suppression levels of direct nanoparticle treatment
at 0.5 mg/mL. In order to rule out the possibility of suppression due to other factors,
blank nanoparticles and media were incubated for the same time frame and tested, with
no statistical difference in suppression (Figure 6-11b).
6.3.7

Evaluation of inflammatory intracellular adhesion molecule (ICAM-1)
expression

Cells treated with TNF-α at a 10 ng/mL concentration for 4 hours had an elevated
level of ICAM-1 expression, 202 ± 25% above untreated cells. Treatment with pure
apigenin at 10 µM reduced ICAM-1 levels to 65 ± 8.5%. The nanoparticle therapies of
apigenin and apigenin PβAE reduced expression levels to 80 ± 9.3% and 97 ± 16% of
unstimulated controls. The unloaded nanoparticles demonstrated no therapeutic efficacy
(Figure 6-12).

107

Tumor cell adhesion
(% of unstimulated control)

250
200
*

*

*

150

*

*

100
50
0
0.03 0.60 0.12 0.25 0.50 1.00 0.25 0.50 1.00 0.25 0.50 1.00
Apigenin particles (mg/mL)

Apigenin PβAE Blank particles
(mg/mL)
particles
(mg/mL)

Figure 6-10: Apigenin and apigenin PβAE nanoparticle tumor cell suppression
activity
Both forms of nanoparticles demonstrate similar suppression activity whereas blank
nanoparticles have no effect. Apigenin PβAE nanoparticles show a shifted suppression
ability due to lower overall loading. After the onset of toxicity higher levels of tumor cell
adhesion are recorded. Dotted line indicates level of tumor cell adhesion in TNF-α
activated controls (*p < 0.05, N=3, M±SE).
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Figure 6-11: Long-term release of apigenin PβAE and tumor suppression activity
(A) Apigenin PβAE nanoparticles have a time-dependent activity due to their long-term
release profile. (B) Blank particles and pure media show no statistically significant
suppression ability. Dotted line indicates level of tumor cell adhesion in TNF-α
stimulated controls (*p < 0.05, N=3, M±SE).

109

6.4 Discussion
As mentioned previously, the anti-inflammatory [253] and antioxidant [254] activity
of naturally-derived flavones provides a promising in vitro treatment avenue and these
materials are applicable in many types of injuries [255] and disease states [256]. Despite
this, using flavones as a therapeutic regime has been plagued by issues translating to in
vivo work due to, in part, by poor solubility, stability, and pharmacokinetics. To address
the issue of stability we have developed a non-free radical-based polymerization scheme
for antioxidants and anti-inflammatories such as quercetin, curcumin, and apigenin. In
their polymeric form these compounds are protected from premature oxidation, and
through careful selection of commonly used reagents in the reaction process, can achieve
desirable delivery rates following degradation. The new apigenin-based PβAE polymer
outlined in this work has been shown to retain activity after complete degradation.
The degradation products of apigenin PβAE do not, however, retain the full activity.
The possible explanation for this could be that the degradation products do not fully
regain their anti-inflammatory properties, either due to incomplete degradation of the
PβAE chains or apigenin
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Figure 6-12: Inflammatory CAM expression in HUVECs
Both pure apigenin and nanoparticle formulations significantly reduce ICAM-1
expression in TNF-α treated HUVECs. Blank nanoparticles provide no therapeutic
benefit. Dotted line indicates level of tumor cell adhesion in TNF-α activated controls (*p
< 0.05, N=5, M±SE).
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multiacrylate to apigenin. This phenomenon has been observed in a previous publication
utilizing antioxidant PβAE polymers [188]. Most interestingly is that our experiments
demonstrate that apigenin has no tumor cell adhesion suppression effect in uninflamed
endothelial cells, lending credence to the link between inflammation, tumor metastasis,
and the ability of flavones to suppress cell adhesion.
To formulate a delivery system for the highly hydrophobic apigenin and apigenin
PβAE, a single-step nanoprecipitation method was utilized. By encapsulating apigenin
and the apigenin PβAE into a nanoparticle formulation, we can confer advantageous drug
delivery properties, such as increased solubility, controllable release, and improved
pharmacokinetics through the masking of PEG moieties. The developed nanoparticles
range in size between 200-250 nm, which is within the generally accepted size to
encourage cellular uptake and internalization [257], with drug loading rates of up to 25%.
Initial cell culture results indicate an order of magnitude decrease in the toxicity
between free apigenin and encapsulated apigenin in particle form (80 µM versus 855 µM,
respectively). This marks an order of magnitude lower threshold of toxicity, due to the
longer term drug release and protection inside a normally inert nanoparticle, compared to
a large bolus application in the free drug form. Also, the unloaded nanoparticles
demonstrated no toxicity up to 5 mg/mL, indicative that the toxicity of these
nanoparticles stems solely from the loaded drug.
Our toxicity model suggests the apigenin PβAE nanoparticles exhibit slightly higher
toxicity (400 µM), possibly due in part to impurities from unreacted amines during
polymer formulation. However, both formulations retain their adhesion suppression
potential. Interestingly, at the highest concentrations of both formulations, the tumor cell
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adhesion increases. We believe that at this dosage, the toxic effects begin to overcome the
anti-inflammatory benefits provided by apigenin. This toxicity at high concentrations has
been observed with our previous antioxidant work [45]. While apigenin PβAE
nanoparticles required a higher incubation concentration to achieve the same effect as
apigenin, it is important to note that the active drug loading content is 41% lower.
Comparing the release kinetics of apigenin and apigenin PβAE nanoparticles, we
observe the most notable trend. Pure apigenin-loaded particles released the majority of
their payload within 18-24 hours, with a significant burst release effect within the first
hour, a common characteristic with PLA/PLGA based systems [258]. In the scenario of
the apigenin PβAE-loaded nanoparticles, a less pronounced burst release is seen,
followed by a sequential linear release for up to 120 hours, a stark contrast from the free
form of apigenin. It is theorized that the diffusion out of the particles is hindered due to
the higher molecular weight of the PβAE. However, it is unclear at this time whether the
enhanced release is due to the possibility of PβAE release then subsequent degradation to
active apigenin in solution or if the PβAE is degrading within the nanoparticle, followed
by diffusing outwards.
To evaluate the potency of this longer term release mechanism, the nanoparticles
were incubated in media at normal cell culture conditions over a 72 hour period of time.
The particles were then separated from the therapeutic-containing media and cells were
dosed with this media. Our results show time-dependent release results with a decrease in
tumor cell adhesion. After 72 hours, cell adhesion is reduced to nearly background levels
(123 ± 12%). Correlating the previous release data with the time-dependent suppression
potential, there is a strong correlation with the whole nanoparticle incubation results. This
113

points to a potentially viable drug delivery platform that could provide a long circulating
and releasing therapeutic to inhibit inflammation-mediated cancer metastasis.
Lastly, in order to derive a link between inflammation and tumor cell adhesion, we
examined the expression levels of the inflammatory marker ICAM-1. As expected, we
observe a pronounced increase in expression levels of HUVECs treated with TNF-α.
Cells treated with pure apigenin do demonstrate the highest level of CAM and tumor cell
adhesion suppression, however a viable treatment utilizing the compound alone would
prove difficult at best, for reasons explained previously. The apigenin and apigenin PβAE
loaded nanoparticles also significantly reduce ICAM-1 expression, down to lower than
constitutive expression in fact, while also retaining the ability to inhibit tumor cell
adhesion with a higher toxicity threshold, and a demonstration of enhanced release
properties with the apigenin PβAE nanoparticles. Figure 6-13 links the correlation to
ICAM-1 expression and tumor cell adhesion suppression. We see that for each
therapeutic treatment, a near linear relationship is formed, while leaning slightly on the
side of higher ICAM-1 suppression. These results suggest a link between the two
properties, and further strengthens the discussion of links between metastasis and
inflammation.
6.5 Conclusions
This work has demonstrated that a novel flavone-based polymeric nanoparticle
system can be used to provide the extended release of active anti-inflammatory
compounds. These nanoparticles have been shown to inhibit tumor cell adhesion to
inflamed endothelial cells through the delivery of viable apigenin. Future work in the
development of targeted nanoparticles through the use of targeting peptides or antibodies
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can potentially enhance the ability to suppress inflammation exclusively at sites of
interest, such as localized chemotherapy or surgical sites.
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Figure 6-13: Tumor cell adhesion verses ICAM-1 expression
Analysis of therapeutic treatment options demonstrates a near linear link between ICAM1 expression levels and the ability for tumor cells to firmly adhere to the HUVEC
monolayer surface. (N = 3 for x: 5 for y, M±SE)
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Chapter 7. Conclusions
In this work, we have developed antioxidant polymers and delivery systems to create
practical therapeutics to treat a variety of injuries and diseases. Initially, we have utilized
nanoparticles of our novel antioxidant polymer, poly(trolox), and modified their surfaces
with monoclonal antibodies. This surface-modification allows for the nanoparticles to be
directed to sites of interest. To use this therapeutic in a practical application, we
investigated the toxicity associated with iron oxide nanoparticles. These particles are
currently being used as MRI contrast agents, drug delivery devices, and chemotherapy
adjuvants. Although these nanoparticles have been regarded as non-toxic, a growing body
of evidence has pointed towards toxicity stemming from free radical generation and
oxidative stress.
We first created antibodies directed towards platelet endothelial cellular adhesion
molecules, a constitutive protein expressed primarily in vascular endothelial cells. These
PTx adhered and internalized specifically to HUVECs and it was found to suppress the
damaging effects of iron oxide nanoparticles. Not only did PTx reduce levels of free
radicals, but it also fully recovered cell viability.
In order to understand the link between oxidative stress and injury further, we
employed PTx again in an in vivo model. By utilizing an inflammation-mediated arthritis
injury in mice, we could further elucidate the connection between inflammation,
oxidative stress, and disease. It was found that PTx did not have any apparent effect on
the arthritic injuries in mice. However, we did observe a significant recovery of
antioxidant capacity and suppression of protein carbonyl content, a marker for oxidative
stress and injury. In addition, PTx also suppressed cytokine expression known to be
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associated with oxidative stress. Further study will be required to tease out the connection
to injury and discrepancy between physical and chemical cues.
With the link between metastasis potential and inflammation well-established, we
hypothesized that our polymers could be used to inhibit the progression of cancer. In our
final study, we utilized our unique poly(beta-amino ester) chemistry to develop a long
term delivery system of anti-inflammatory polymers.
Linear chain polymers of apigenin were encapsulated in mPEG-PLA to form a
biocompatible polymer capable of delivering active apigenin over a 72 hour period.
These PβAE particles were less toxic and deliverable at higher dose compared to the
extremely hydrophobic native apigenin. It was found that these apigenin PβAE
nanoparticles were able to inhibit the ability of highly metastatic tumor cells to adhere to
healthy vascular cells. The long term release component also allows for continual
therapeutic dosing for the entire course of the natural inflammation cascade.
By demonstrating that antioxidant polymer therapy can be utilized to treat relevant
injuries and diseases, we come one step closer to realizing far reaching clinical
applications.
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APPENDIX
Based on the research article:
Mo Dan, David Cochran, Robert Wydra, Robert Yokel, Thomas Dziubla. “Binding,
transcytosis, and biodistribution of anti-PECAM-1 iron oxide nanoparticles for braintargeted delivery” PLOS ONE.

Introduction
Multifunctional superparamagnetic iron oxide nanoparticles (IONPs) have various
applications, such as diagnosis and therapy of the central nervous system (CNS) [259,
260]. For example, IONPs have drawn increasing attention as T2 magnetic resonance
imaging (MRI) contrast agents to evaluate blood-brain barrier dysfunction related to
tumors and other pathologies such as stroke and carotid atherosclerosis in clinical and
preclinical studies [261, 262]. Multifunctional IONPs also provide the possibility to
deliver therapeutic agents to the brain and concurrently monitor their tissue distribution
using MRI [263, 264]. One of the challenges for CNS applications of IONPs is the ability
to cross the highly restricted blood-brain barrier (BBB). Previous research has suggested
evidence of IONP flux across the BBB by analyzing whole brain concentration.
However, there have been no reports distinguishing between IONPs in the brain vessels
and BBB cells [265], or therapeutic efficacy of co-delivered compounds in animal
models of brain tumors [266]. To advance the potential applications of multifunctional
IONPs in the CNS, there is an urgent need to understand how they associate with, and
transcytose across, the BBB in vitro and in vivo.
Brain capillary endothelial cells cooperate with pericytes, astrocytes, and neurons to
generate and maintain the unique barrier properties of the BBB. The BBB plays a crucial
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role in safeguarding the brain from endogenous and exogenous compounds, which
includes most therapeutics [267]. A recent study evaluated the uptake and flux of IONPs
using human brain-derived endothelial cells. IONP flux without targeting moieties on the
surface was very limited under normal conditions [268]. A promising strategy to enhance
IONP flux across the BBB is to use a BBB targeting moiety. Platelet-endothelial cell
adhesion molecule (PECAM-1) (CD31) is a member of the immunoglobulin superfamily
that is constitutively expressed on endothelial cell membranes and is involved in
transcytosis of activated leukocytes across the BBB in neuroinflammation [269-271].
Furthermore, significant upregulation of PECAM-1 in neuroinflammation provides a
potential to target the CNS for the treatment of neurological conditions such as stroke and
brain tumor [271]. Pure PECAM-1 antibody has been shown to target the endothelial
lumen, but does not internalize into endothelial cells [195]. However, anti-PECAM-1
coated nanocarriers can enter the endothelial cells through a unique vesicular
internalization pathway, [190]. Anti-PECAM-1 antibodies conjugated to diverse
therapeutic cargoes and nanocarriers provided robust intracellular drug delivery into
endothelial cells [183]. However, how anti-PECAM-1 nanocarriers associate with and
traffic across the BBB, one of the most important endothelial cell barriers, still needs to
be defined.
We hypothesized that PECAM-1 antibody will increase IONP BBB association,
trafficking across the BBB, and change its distribution profile in vitro and in vivo. In this
study, we characterized anti-PECAM-1 IONPs for size, adhesion to immortalized human
brain capillary endothelial (hCMEC/D3) cells, and stability in blood. We investigated the
association, and flux across the BBB over 6 hours, of anti-PECAM-1 IONPs using
120

hCMEC/D3 cells. Furthermore, anti-PECAM-1 IONP brain accumulation and
biodistribution in peripheral organs were studied in Sprague Dawley rats. The capillary
depletion method was used to test anti-PECAM-1 IONP in vivo distribution between the
BBB endothelial cells and brain parenchyma. The results of this study demonstrate the
potential of anti-PECAM-1 IONPs to target and transcytose across the BBB and enter
into the brain parenchyma, providing valuable insight into the feasibility of anti-PECAM1 IONP as a brain targeting MRI contrast agent and/or drug delivery system for CNS.
Materials and Methods
Ethics Statement
This study used 21 male Sprague-Dawley rats, weighing 300 ± 25 g (mean ± SD),
that were housed individually prior to study in the University of Kentucky Division of
Laboratory Animal Resources Facility. Animal work was approved by the University of
Kentucky Institutional Animal Care and Use Committee (Protocol 2008-0272). The
research was conducted in accordance with the Guiding Principles in the Use of Animals
in Toxicology.
Reagents
Mouse anti-human anti-PECAM-1 was created and purified in house through the use
of a hybridoma cell line (P2B1) purchased from the Developmental Studies Hybridoma
Bank (Iowa City, IA). For in vivo studies, a mouse anti-rat anti-PECAM-1 (Clone TLD3A12) was purchased from Millipore (Billerica, MA). Nonspecific mouse IgG was from
Jackson Immuno (West Grove, PA). Na125I was purchased from Perkin Elmer (Boston,
MA). All other reagents were from Sigma-Aldrich (St. Louis, MO).
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Iron oxide nanoparticle synthesis
IONPs were synthesized using a previously reported method [166]. Briefly, ferric
chloride hexahydrate (Fe3+) and ferrous chloride tetrahydrate (Fe2+) were dissolved in
deionized water (Fe3+ :Fe2+ = 2:1), followed by adding ammonium hydroxide dropwise
under an N2 atmosphere at 85 ºC. After 1 h, the solution was placed on a magnet to
collect black brown particles, which were washed repeatedly using pure ethanol [189,
272]. IONPs were dried overnight in a vacuum drying oven. Properties, such as size and
zeta potential of the IONPs, were determined in our laboratories. All of the methods have
been previously reported [273].
Protein iodination for antibody tracing
IgG and the anti-PECAM-1 antibody were labeled with Na125I using the Iodogen
method. In brief, 100 µg of antibody was mixed with 15 µCi of Na125I for 5 minutes in
glass tubes coated with Iodogen reagent. Following the reaction, the now-labeled protein
was purified using Bio-Rad Labs packed spin columns (Hercules, CA). The extent of
iodination was determined by protein precipitation followed by analysis of radioactivity
in the pellet and supernatant [274].
Preparation and characterization of antibody-modified iron oxide surfaces
Iron oxide nanoparticles were suspended in PBS and sonicated with a probe sonicator
at a power output of 10 W for 1 minute, then transferred to a sonication bath for 30
minutes prior to surface coating. To couple anti-PECAM-1 or IgG antibody to iron oxide
nanoparticles, a physioabsorption technique was employed. Either anti-PECAM-1 or IgG
antibodies were incubated with the nanoparticles at a solution concentration equivalent to
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10,000 antibodies/µm2 particle surface area, 1.2 times the theoretical monolayer coating
based on antibody size and particle surface area. Radiolabeled anti-PECAM-1 or IgG in
PBS was added to the suspended nanoparticles and incubated for 1 hour at 25°C.
Particles were washed 3 times by centrifugation for 30 minutes at 22,000g and suspended
in 1% BSA-PBS. The antibody was traced in both supernatant and pellets using a
PerkinElmer 2470 Automatic Gamma Counter to determine the extent of surface
coverage.
Antibody-modified iron oxide nanoparticle stability in blood
To determine coating stability in vivo, particles were incubated in heparin-treated
whole rat blood at 37°C for 24 h at equivalent concentrations utilized in vivo (blood to
nanoparticles, 0.015 mg/ml). At pre-determined time points, aliquots of whole blood were
centrifuged and separated from the nanoparticles and analyzed on the gamma counter.
Cell lines and culture conditions
Immortalized human brain capillary endothelial cells (hCMEC/D3) were obtained
under license from INSERM, France. The cells were maintained in endothelial growth
medium-2 supplemented with 2.5% fetal bovine serum, 1% penicillin and streptomycin,
0.1% fibroblast growth factor, 0.01% hydrocortisone and 0.025% vascular endothelial
growth factor, insulin-like growth factor and endothelial growth factor, under 37°C and
5% CO2. Cells were passaged into collagenated culture flasks every 3-4 days when they
reached approximately 85%-95% confluence [275-277].
PECAM-1 antibody binding affinity to the human brain endothelial cell line
hCMEC/D3
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hCMEC/D3 cells were seeded on 36 well plates at a density of 50,000 cells/cm2. They
were incubated with serial dilutions from 0.78 to 100 nM of 125I anti-PECAM-1 or 125I
IgG antibodies for 2 h (n = 3). Donor chamber supernatant was collected and the cells
were washed 3 times with PBS at 4 °C. The hCMEC/D3 monolayer was lysed with 1%
Triton X-100 in 1.0 N NaOH. The cell lysate and supernatant (including the washing
solution) radioactivity were measured using a Wallac 1470 Wizard™ gamma counter.
Bmax and Kd were calculated using GraphPad Prism (GraphPad Sofware, San Diego, CA,
USA).
Anti-PECAM-1 IONP binding and flux using the human brain endothelial cell line
hCMEC/D3 in vitro BBB model
hCMEC/D3 cells were seeded on type I collagen pre-coated 6 well Transwell filters
(polycarbonate 12 mm, pore size 3.0 µm) at a density of 50,000 cells/cm2. Flux assays
were performed 7-10 days after seeding [275, 276]. The tightness of the hCMEC/D3
monolayer was measured as transepithelial electrical resistance (TEER) using a
RMA321-Millicell-ERS voltohmmeter (Millipore Corp, Billerica, MA). To monitor flux
through the paracellular pathway, lucifer yellow (LY, 100 µM) was added to the medium
on the donor side of the cells. Samples of the medium from the donor chamber were
collected at time zero and from the receiving chamber hourly for 6 h for LY
concentration analysis. Fluorescence was determined in SpectraMax M5 Multi-Mode
Microplate Reader (Molecular devices, Sunnyvale, CA) at λex\λem = 450/530 nm and
compared with a standard of LY in endothelial growth medium-2.
Anti-PECAM-1 and IgG IONPs were introduced into the donor chamber at 0.05
mg/mL, as used in our previous cytotoxicity study on IONPs [273]. Samples (100 µL)
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were collected from the donor chamber at time 0 and the receiving chamber hourly for 6
h for iron concentration analysis by inductively coupled plasma mass spectrometry (ICPMS) (Agilent 7500cx, Santa Clara, CA, USA). The donor chamber was removed and the
cells washed 3 times using PBS at 4 °C. The hCMEC/D3 monolayer was lysed with 1%
Triton X-100 in 1.0 N NaOH. Iron concentration in the cell lysate and supernatant
(including washing solution) were measured using ICP-MS. Flux rates of LY and
nanoparticles were calculated by linear regression for the first 6 h. Two-way ANOVA
followed by Bonferroni multiple comparisons was used to test for significant flux
differences among the treatment groups and times using GraphPad Prism (GraphPad
Software, San Diego, CA). Statistical significance was accepted at p < 0.05.
Brain targeting and biodistribution by anti-PECAM-1 IONPs
Antibody-coated iron oxide nanoparticles were prepared similarly as before with one
exception. Both anti-PECAM-1 and IgG coated particles were incubated with 5% 125I
labeled IgG at a concentration of 10 mg/kg. This was done to prevent any detached
labeled antibody from accumulating in the vasculature, thus providing a false positive for
adhesion. Carotid artery injection was employed to delivery 10 mg/kg 125I anti-PECAM-1
IONPs (n = 3) and 125I IgG IONPs (n = 3). Briefly, the rat was anesthetized under
ketamine/xylazine anesthesia (75 and 5 mg/kg), and its left carotid artery exposed.
Following ligation of the external carotid, occipital and common carotid arteries, PE60
tubing containing heparin (100 U/ml, in 0.9% NaCl) was inserted into the common
carotid. The 10 mg/ml 125I anti-PECAM-1 IONPs and 125I IgG IONPs were injected at 1
ml per min at a dose of 10 mg/kg. All the rats were sacrificed 10 min after infusion. The
brain was harvested and cleaned of meninges and surface vessels. Blood and organs such
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as the liver, spleen and lung were collected for biodistribution analysis using the gamma
counter .The results were compared between 125I anti-PECAM-1 and 125I IgG IONPs
using t-test or one-way ANOVA. The localization ratio (LR) was calculated as the
percent of the injected dose per gram of tissue divided by percent of the injected dose per
gram of blood. The specificity index was calculated as the LR of the targeted formulation
(anti-PECAM-1 IONPs) divided by the non-targeted counterpart (IgG IONPs). The
specificity index indicates specific targeting to organs, normalized by organ weights and
the faction contained in blood [278]. One-way ANOVA followed by Tukey’s test was
used to test for significant differences of IgG IONP and anti-PECAM-1 IONP
biodistribution among different organs. All results are reported as mean ± SD. Statistical
significance was accepted at p < 0.05.
BBB integrity assessment
Five minutes before termination, the rat was given 6 mg Na fluorescein (334 Da) i.a.
in 1 ml saline over 40s as a BBB permeability marker. Postmortem brain cortex was
obtained to quantify fluorescein content. Fluorescence was determined in a SpectraMax
M5 Multi-Mode Microplate Reader (Molecular devices, Sunnyvale, CA) at λex\λem =
493/514 nm. The results among control, IgG IONP, and anti-PECAM-1 IONP groups
were compared using one-way ANOVA (GraphPad Software, San Diego, CA).
Anti-PECAM-1 IONP distribution between the BBB endothelial cells and brain
parenchyma using the capillary depletion assay
The capillary depletion method was used to separate brain parenchyma from capillary
tissue [279, 280]. After a 10 mg/kg anti-PECAM-1 IONP injection in 1 ml over 1 min, a
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20 s washout was conducted using PBS at a flow rate of 20 ml/min immediately before
decapitation [281]. The forebrain from the left hemisphere was isolated from 125I antiPECAM-1 IONP and 125I IgG IONP treated rats (n = 3) and the lateral ventricle choroid
plexus in the perfused hemisphere removed. The tissue was homogenized in 3.5 ml of
buffer containing 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM NaH2PO4, 1 mM
MgSO4, 10 mM glucose and 10 mM HEPES at pH 7.4. Dextran (70,000 g/mol) was then
added to 18% (w/v) and the sample further briefly homogenized. After centrifugation at
5400 x g for 15 min at 4 ºC, the supernatant (brain rich fraction) and pellet (capillary rich
fraction) were carefully separated for measurement of 125I by gamma counter. The
percentage of the forebrain 125I in the capillary rich fraction is as follows:
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 125𝐼𝐼 𝑖𝑖𝑖𝑖 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑟𝑟𝑟𝑟𝑟𝑟ℎ 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓
�
� ∗ 100
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 125𝐼𝐼 𝑖𝑖𝑖𝑖 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑟𝑟𝑟𝑟𝑟𝑟ℎ 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 + 𝑐𝑐𝑐𝑐𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓

The apparent permeability coefficient
The apparent permeability coefficient (Papp, cm/s) of LY, IgG IONPs and antiPECAM-1 IONPs was calculated using GraphPad Prism. The first 6 h flux data were
used with R2 cutoff > 0.8. The Papp in (cm/s) was calculated using the equation: Papp =
(ΔQ/Δt)/(area*CD) [282]. ΔQ/Δt is the linear appearance rate obtained from the profile of
the transported amount of the substrate against time (mg/s). CD is the initial donor
concentration of LY or nanoparticles (mg/mL). Area is the surface area of the cell
monolayer (4.67 cm2 for a 6-well plate).
Results
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Anti-PECAM-1/IgG coating efficiency
After removal of unbound antibody, the surface coverage was determined to be 63.6
± 8.4% (Figure 1A). Based on the primary nanoparticle size of 80 nm (Figure 1B), this
corresponds to 19.1 µg antibody/mg of nanoparticle or 105 antibody
molecules/nanoparticle. DLS measurements showed the size increased from 80 nm to 130
nm after addition of anti-PECAM-1 (Figure 1B), indicating uniform coating with slight
aggregation, as the antibody size is ~15 nm in length. The zeta potential of the
nanoparticles decreased from -10 to -8 mV (Figure 1C).
Stability of antibody-coated iron oxide nanoparticles in whole blood
Because anti-PECAM-1 IONPs and IgG IONPs were prepared by surface antibody
adsorption, their stability in blood is very important for in vivo study. The 125I labeled
IgG antibody exhibited minimal detachment from nanoparticles for up to 4 h at 37°C. At
4 h, only 6.4 ± 1.2% of labeled antibody was detected in the heparin-treated blood after
centrifugation. Between 4 and 24 h this increased to 46.2 ± 9.5%, likely due to the
antibody on the nanoparticle surface being replaced with higher affinity serum proteins
(Figure 2). The insignificant coating loss over 4 h suggests these nanoparticle
modifications will stay stable throughout the circulation life and time frame of in vivo
experiments.
PECAM-1 binding affinity to the human endothelial cell hCMEC/D3
hCMEC/D3 is a human BBB cell line developed in 2005. Previous research showed
that it expressed PECAM-1 [277]. However, the binding affinity between hCMEC/D3
and PECAM-1 antibody was not known. Figure 3 shows that anti-PECAM-1, but not
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non-specific control IgG, adhered specifically to the BBB cell model. The predicted
antibody saturation (Bmax) was determined to be 16.94x105 molecules/cell, with a binding
constant (Kd) of 32 nM, which is relatively low compared with a designed PECAM-1
antibody (a paired monoclonal antibody) for vascular targeting, with reported affinities
between 0.5-5 nM [283]. However, previous research showed that relatively low affinity
antibodies boost brain uptake by transcytosis targeting [284]. In the next experiment,
anti-PECAM-1 IONP flux across the human endothelial cell hCMEC/D3 was tested.
CNA-IONP flux and cell association using a hCMEC/D3 in vitro BBB model
The TEER of the hCMEC/D3 in vitro BBB model (Figure 4) was tested every other
day after the cells were seeded. After 7-10 days, the resistances were > 90 Ω/cm2, similar
to previously reported [275]. The permeability coefficient of LY, the indication of
paracellular flux, was 2.9 ± 0.2 x 10-6 cm/s.
Anti-PECAM-1 IONP flux was significantly higher than anti-IgG IONPs and LY
from 3 h to 6 h. The permeability coefficient after 6 hours of anti-PECAM-1 IONPs was
6.7 ± 0.2 x 10-6 cm/s, versus 4.8 ± 0.2 x 10-6 cm/s for IgG IONPs, and 2.9 ± 0.2 x 10-6
cm/s for LY (Figure 5A). After 6 h, 30% of anti-PECAM-1 IONPs was in the receiving
chamber and ~ 45 % of anti-PECAM-1 IONPs was associated with the hCMEC/D3 cells,
significantly higher than IgG IONPs (Figure 5B). PECAM-1 antibody significantly
enhanced the flux of IONPs across the hCMEC/D3 monolayer in vitro. In the next
experiment, anti-PECAM-1 IONP brain targeting, accumulation, and biodistribution were
studied using Sprague Dawley rats.
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Anti-PECAM-1 IONP association and biodistribution in brain and peripheral
organs
Using 125I tracing, we tested anti-PECAM-1 IONP targeting ability to brain and
peripheral organs. As shown in figure 6A, the % dose per mL of blood in anti-PECAM-1
IONP treated rats was significantly lower than IgG IONP treatment, suggesting increased
removal from blood and enhanced tissue accumulation. Ten min after infusion, 0.11 ±
0.01 % of the anti-PECAM-1 IONPs dose was associated with each gram of brain, which
was significantly higher than anti-IgG IONPs (Figure 6B). The specificity index (the ratio
between targeted and non targeted control) was calculated to test the anti-PECAM-1
IONPs brain targeting ability. Anti-PECAM-1 IONPs specificity in the brain was 5-fold
higher than with IgG IONPs (Figure 6C). PECAM-1 targeting did not change antiPECAM-1 IONP distribution in liver and spleen compared with IgG. However, antiPECAM-1 IONP accumulation was significantly increased in the lungs (Figure 7).
Effect of Anti-PECAM-1 IONPs on blood-brain barrier integrity
Since anti-PECAM-1 IONP brain association was significantly increased, it was
important to determine whether that changed the BBB permeability. Ten min after antiPECAM-1 IONP injection the concentration of the BBB permeability marker,
Fluorescein in the brain, did not change significantly compared with the control and IgG
IONP groups (Figure 8).
Anti-PECAM-1 IONP distribution between brain capillary cells and brain
parenchyma
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For brain delivery systems, determination of whether or not they can enter the brain
parenchyma is crucial. Our permeability results showed that anti-PECAM-1 IONPs did
not alter BBB permeability. Understanding the anti-PECAM-1 IONP distribution
between the brain capillary cells and parenchyma would provide evidence for
transcellular flux. The capillary depletion results showed that 10 min after infusion, 82 ±
12% of anti-PECAM-1 IONPs were still associated with the capillary fraction and 17 ±
12% of them entered the brain (Figure 9). The capillary depletion assay was also carried
out with brain from IgG IONPs treated rats. However, because of the low brain
association of IgG IONPs, all radioactivity level readings were indistinguishable from
background radioactivity.
Discussion
The use of vasculature-targeting antibodies, especially against PECAM-1, has been
utilized before for lung targeting, injury treatment, [182] and as tumor contrast agents
[285]. Anti-PECAM-1 nanocarriers can internalize into the cell through cellular adhesion
molecule (CAM)-mediated endocytosis [190], which provides the potential to target the
BBB and increase nanocarrier flux across the BBB. Previous research showed that IONPs
coupled with affinity moieities targeted to receptors, such as transferin, can facilitate
IONP flux across the BBB [286]. However, little is known whether anti-PECAM-1
surface-modified IONPs enhance brain flux across the BBB and change the distribution
of IONPs between the BBB and brain parenchyma. In this study, we explored antiPECAM-1 IONP targeting, transcytosis across the BBB, and biodistribution in the brain
and peripheral organs.
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We demonstrated that iron oxide nanoparticles can be sufficiently coupled with both
IgG and anti-PECAM-1 using a non covalant physioabsorption strategy. It was
determined that over 60% of the nanoparticle surface was coated with antibody (105
antibody molecules per single nanoparticle). Previous research has demonsatrated that
clustering of the CAM through antibody binding can result in efficient internalization of
anti-PECAM-1 nanoparticles, depending upon epitope of binding [190]. Using a non
covalant targeting strategy, it was expected that upon contact with serum proteins they
would inactivate the targeting coating, lowering the treatment efficacy. Contrary to this, it
was seen that the coating on these nanoparticles stays intact for up to 4 h, vastly longer
than the circulation half life of up to 2 h for uncoated particles [287]. The IgG IONPs
and anti-PECAM-1 we developed have desirable properties to investigate BBB targeting
and flux in vitro and in vivo.
In our in vitro flux study, LY showed higher flux at 1 h compared with anti-PECAM1 IONPs and IgG IONPs. At 2 h, the flux of LY, anti-PECAM-1 IONPs and IgG IONPs
were similar. After 2 h, anti-PECAM-1 IONPs flux was significantly higher than LY and
IgG IONPs. These results provided evidence that the paracellular pathway was not the
major pathway for anti-PECAM-1 IONPs flux. Anti-PECAM-1 IONPs use a different
mechanism of flux across the BBB compared with IgG IONPs. There are multiple
pathways for internalization involving vesicles < 300 nm in diameter. Clathrin- and
caveolea-mediated endocytosis are the two major pathways for nanoparticle
internalization [288-291]. IgG IONPs are likely to be taken up through these pathways.
Limited transcytosis was observed in our study, which was consistent with a previous
study in which the flux of three different surface-charged IONPs was studied across a
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human BBB model in vitro. Very limited flux was observed over 25 h [268]. On the other
hand, clustered PECAM-1 can be internalized by a novel endocytic pathway, CAM
endocytosis [190], which was distinct from clathrin and caveolin-mediated endocyosis
[292, 293]. Our in vitro flux study showed that PECAM-1 antibody surface modification
significantly improved BBB targeting and flux across the BBB. Previous research
showed that intercellular adhesion molecule 1(ICAM-1)-targeted nanocarriers, which
also use the CAM-endocytosis pathway, provide considerable promise to enhance
delivery of larger multivalent carriers to the CNS [278]. Another study also showed that
anti-PECAM-1 nanocarriers demostrated significantly higher brain association [294].
However, they analyzed whole brain tissue including the BBB, brain parenchyma and the
blood in the brain vessels. The present study provides a better understanding of the
assocation and flux of anti-PECAM-1 nanoparticles across the BBB in vitro and in vivo.
In our in vivo study, anti-PECAM-1 IONPs did not change BBB permeability, further
suggesting that anti-PECAM-1 IONPs crossed the BBB through a transcellular pathway
rather than a paracellular pathway. We are not aware of any reports on how antiPECAM-1 IONPs influence BBB permeability. However, previous research showed that
anti-PECAM nanocarriers did not change endothelial monolayer integrity compared with
a IgG nanocarrier [294]. The lack of anti-PECAM IONP increased BBB permeability
decreases its potential adverse effects related to the BBB.
The level of anti-PECAM-1 IONPs in the blood was significantly lower than IgG
IONPs, suggesting enhanced tissue accumulation. The results were consistent with antiPECAM-1 IONP brain association results. Compared with IgG IONPs, anti-PECAM-1
IONP significantly increased IONP brain association 10 min after infusion. There was
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0.11± 0.01 % of the dose associated with a gram of brain tissue 10 min after infusion. For
comparison, the brain uptake of morphine, a neuroactive lipid soluble small molecule, is
0.0081± 0.001% of the dose /g rat brain [295]. The uptake of anti-PECAM-1 IONPs was
higher than morphine, a regularly administered neuroactive small molecule with the
capability of crossing the BBB. This demonstrates the potential application of PECAM-1
antibody for brain delivery. The transferrin receptor is the most studied targeting receptor
for brain uptake [296]. Most previous studies of transferrin-surface-modified
nanoparticles focused on the improvement of diagnosis and therapeutic effects rather than
brain uptake [286, 297]. The brain delivery of the transferrin ligand was less than 0.3% of
the dose using a healthy animal model [298]. A recent study compared ICAM-1 antibody
and transferrin-surface-modified nanocarriers for brain targeting. It was found that they
are both effective, but transferrin showed more advantages on smaller conjugates and
ICAM-1 worked better for larger multivalent carriers [24]. In our study anti-PECAM-1
IONPs showed a similar specificity index as previously reported anti-ICAM-1
nanocarriers [278]. We expected PECAM-1 antibody would show similar brain targeting
as ICAM-1, however, more research needs to be done to compare PECAM-1, ICAM-1
and transferrin for brain targeting. Furthermore, the actual extent of transferrin
transcytosis is still unknown. Some studies showed that only a miniscule amount of
transferrin was trancytosed across the brain capillary endothelial cells and accumulated in
the brain [299, 300]. Our in vitro results provide evidence that anti-PECAM-1 IONPs can
transcytose across a human BBB monolayer in vitro model.
We investigated the distribution between the BBB and brain parenchyma using the
capillary depletion method to better characterize anti-PECAM-1 IONP transcytosis in
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vivo. Our results showed that 10 min after injection, 17 ± 12% of anti-PECAM-1 IONPs
crossed the BBB and associated with brain parenchyma. However, the majority of antiPECAM-1 IONPs was still associated with the BBB cells. CAM-mediated endocytosis is
a relatively slow process. One study investigated anti-PECAM nanocarrier internalization
into human endothelial cells over time. After 15 minutes, 20% of anti-PECAM
nanocarrier was internalized. However, there is little known about anti-PECAM-1
transcytosis [294]. Our in vitro flux study showed that 4.5% of anti-PECAM-1 IONPs
flux cross the BBB monolayer over 1 h. Our studies demonstrated the potential of antiPECAM-1 IONPs to cross the BBB in vitro and in vivo. However, a longer time point
study is required to better understand how effectively anti-PECAM-1 enhances flux
across the BBB.
The biodistribution results of anti-PECAM-1 IONPs demostrated that PECAM-1
antibody did not increase anti-PECAM-1 IONP accumulation in the liver and spleen 10
min after injection. More study at longer time point is needed to fully understand the
depostion of anti-PECAM-1 IONP in the liver and spleen. However, PECAM-1 antibody
significantly increased the IONP accumulation in the lung. This result was consistent
with previous reports that an anti-PECAM-1 nanocarrier is a good candidate for
pulmonary targeting [301, 302]. This is due to the massive surface area provided by lung
capillary beds. For brain targeted delivery, high accumulation in the lung has potential to
cause side effects there. However, we can take advantage of this properties for certain
diseases. For example, about 15-20% of patients with non-small cell lung cancer
(NSCLC) develop brain metastasis [303]. Anti-PECAM-1 nanocarriers can target lung
and brain simultaneously and be taken up through the CAM-mediated endocytosis
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pathway [294]. Furthermore, recent clinical research showed that PECAM-1 could be a
potential prognostic factor and a novel therapeutic target for the effective treatment of
NSCLC [304]. Therefore, anti-PECAM-1 IONPs have potential to be used to target lung
and NSCLC, while treating potential brain metastasis. More research needs to be
conducted to test anti-PECAM-1 IONPs in a brain metastasis model and investigate how
they associate with the blood tumor barrier and tumor cells.
Conclusions
This work demostrated that anti-PECAM-1-modified IONPs enhance flux across the
BBB in vitro and in vivo, which holds promise to deliver IONPs or other therapeutic
agents to the CNS without compromising BBB permeability. This effect was a result of
both the capacity of anti-PECAM-1 IONPs to target the BBB and the ability to
transcytose across into the brain. Meanwhile, anti-PECAM-1 IONPs demonstrated
increased lung accumulation, which provides the potential to simultaneously target lung
and lung cancer derived-brain metastasis. Future studies investigating anti-PECAM-1
IONPs using a lung cancer brain metastasis model in vivo should provide evidence on
how anti-PECAM-1 IONPs associate with the blood tumor barrier and metastatic brain
tumor. Anti-PECAM-1 IONPs have great potential to be employed in the diagnosis and
therapy of CNS diseases such as NSCLC-originating brain metastasis.
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Figure 1. Surface modification of IONPs by anti-PECAM-1 antibody. Iron oxide
nanoparticles were incubated with excess 125I labeled antibody and purified by
centifugation. The bound antibody was tested after each centifugation (A). Size of
IONPs before and after anti-PECAM-1 antibody surface modification (B). Zeta potential
of IONPs before and after anti-PECAM-1 antibody (C). (N = 3, mean ± SD)
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Figure 2. Antibody coating stability in whole blood. 125I labeled nanoparticles show
minimal detachment of coating for up to 4 hours, suggesting coating stability and
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Figure 3: PECAM-1 antibody binding affinity on immortalized human brain endothelial
cells (hCMEC/D3). IgG exhibited undetectable levels of binding, whereas anti-PECAM-
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Figure 4. Anti-PECAM-1 IONP flux across hCMEC/D3 cells and cell association results.
Anti-PECAM-1 IONP (0.05 mg/ml), IgG IONP (0.05 mg/ml) and LY (100 µM) flux
across hCMEC/D3 cells for 6 h (A). Anti-PECAM-1 IONP and IgG IONP distribution in
the donor and receiving chambers and hCMEC/D3 cells at 6 h (B). (N = 3, mean ± SD)
* Significantly different compared to IgG IONPs
A

35
30

% of dose [Fe]

*

Lucifer Yellow
IgG IONPs
Anti-PECAM-1 IONPs

*
*

25
20

*

15
10
5
0
0

B

60

2

4
Time (hours)

6

8

IgG IONPs
Anti-PECAM-1 IONPs

% of dose [Fe]

50
40

*
*
*

30
20
10
0
Donor

Receiving

140

Cells

Figure 5: Brain association and blood % of dose of anti-PECAM-1- and IgG IONPs. The
brain (A) and blood (B) levels of 125I labeled anti-PECAM-1-IONPs after intra-arterial
infusion in rats, expressed as the percentage of injected dose (% Injected Dose (ID), 10
mg/kg). Specific tissue accumulation of anti-PECAM-1 IONPs compared with IgG
IONPs in brain, calculated as the specific index (SI). SI values above 1 represent specific
targeting in an organ over IgG IONPs (C). * Significantly different. (N = 3, mean ± SD)
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Figure 6: Biodistribution of IgG IONPs and anti-PECAM-1 IONPs in rats. The liver,
spleen and lung levels of 125I labeled anti-PECAM-1 IONPs measured 10 min after intraarterial infusion in rats, expressed as the percentage of injected dose (%ID, 10 mg/kg). *
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10
9
8
7
6
5
4
3
2
1
0

IgG IONPs

*

Anti-PECAM-1 IONPs

Liver

Spleen

142

Lung

Figure 7: BBB permeability measured by fluorescein concentration 10 min after
completion of intra-arterial infusion in rats. Rats received saline, 10 mg/kg IgG IONPs, or
10 mg/kg anti-PECAM-1 IONPs and were terminated 10 min after infusion. (N = 3,
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Figure 8: Capillary depletion results. The level of anti-PECAM-1 IONPs and IgG IONPs
concentrations in the capillary-rich fraction and brain-rich fraction. (N = 3, mean ± SD).
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